



© Jenny Thompson/fotolia.com



## INVITATION PROGRAMME Call for Abstracts / Scientific Programme

WFSBP Congress 2017

# 13<sup>th</sup> World Congress of Biological Psychiatry

18 – 22 June 2017

Copenhagen, Denmark

Bella Center Copenhagen

[www.wfsbp-congress.org](http://www.wfsbp-congress.org)

Organised by: World Federation of Societies of Biological Psychiatry

Hosted by the Danish Society of Biological Psychiatry



## Table of Contents

Page

<b>3</b>	<b>Invitation to the 13<sup>th</sup> World Congress of Biological Psychiatry</b>
<b>4</b>	<b>About WFSBP</b>
<b>5</b>	<b>About the WFSBP Congress 2017</b>
	Congress Administration
	WFSBP Executive Committee
	International Scientific Programme Committee
	Honorary Committee (HC)
	National Presidents
	Chairs of the Local Organising Committee (LOC)
	Congress Ambassadors
	<b>Congress Programme</b>
<b>7</b>	Colour Legend
<b>8</b>	Preliminary Scientific Programme Schedule
<b>13</b>	Preliminary Scientific Programme
<b>39</b>	Topics
<b>41</b>	Call for Abstracts for Free Communications and Posters
<b>42</b>	Format Descriptions of the Scientific Sessions
<b>43</b>	WFSBP Awards
<b>44</b>	Congress Information
<b>45</b>	General Information

### WFSBP GLOBAL HEADQUARTERS

Zum Ehrenhain 34  
22885 Barsbüttel, Germany  
Phone: +49-40-670 882 90  
Fax: +49-40-670 328 82 91  
Email: [info@wfsbp.org](mailto:info@wfsbp.org)  
[www.wfsbp-congress.org](http://www.wfsbp-congress.org)

### CONGRESS VENUE

Bella Center Copenhagen  
Center Boulevard 5  
2300 Copenhagen S, Denmark  
[www.bellacentercopenhagen.dk](http://www.bellacentercopenhagen.dk)

### CONGRESS AND EXHIBITION OFFICE

**CPO**HANSER<sup>®</sup>  
SERVICE

Phone: +49-30-300 669-0  
Email: [wfsbp2017@cpo-hanser.de](mailto:wfsbp2017@cpo-hanser.de)

## Invitation to the 13<sup>th</sup> World Congress of Biological Psychiatry



Masatoshi Takeda



Constantin R. Soldatos



Gregers Wegener

Dear Colleagues,

It is both an honor and a privilege to welcome all of you to the 13<sup>th</sup> World Congress of Biological Psychiatry in Copenhagen, 18–22 June 2017, which will be an excellent setting to discuss the current progress in molecular biology, the development of novel drugs based upon new concepts, and the advances in modern neuroscience that will change our approach to psychiatric disorders and our attitudes towards mental health care. It is the time for biological psychiatry to be developed into the new stage where biopsychosocio-spiritual aspects are integrated for the betterment of patients and families with mental and psychiatric disorders. The field of biological psychiatry is expanding by the development of bioinformatics (genomics, transcriptomics, proteomics) identifying importance of glycome, lipidome, metabolome, and desease, and brain activity mapping methodology.

Looking back a few examples of previous world congress of biological psychiatry in Paris (2009), Prague (2011), Kyoto (2013), and Athens (2015), it is remarkable to have witnessed significant contribution of biological psychiatry research into the diagnosis, treatment, care, and even prevention of psychiatric and mental disorders.

The field of biological psychiatry is rapidly developing, reaching the new stage of clinical application. Genetic engineering, iPS cells, brain mapping, and other new technologies have been integrated into the translational research in the field. Modified electroconvulsive therapy (mECT), repetitive transcranial stimulation (rTMS), near-infrared spectroscopy (NIRS), and decoded neurofeedback (DecNef) are examples of recent application in biological psychiatry. Considering the impact of most CNS disorders, biological psychiatry is expected to fill in the unmet need for CNS drugs including new generation antipsychotics, anti-depressants, anti-epileptics, anxiolytics, and sleep inducers, and others. Biological psychiatry is the field where academia and industry should proceed together aiming for the developing of new methods of diagnosis and treatment of CNS disorders.

We are confident that the 13<sup>th</sup> World Congress of Biological Psychiatry in Copenhagen will be the superb setting for presentation and discussion of recent findings in biological psychiatry. To this end, 5 Lectures, 3 Debates, 12 Task Force Symposia/Workshops and 83 independent Symposia/Workshops are already forming the core scientific programme; all of them on very interesting topics to be presented by prominent researchers-scientists in their respective fields.

We trust that the breadth of topics our congress is tackling, will encourage many more colleagues around the world to submit their recent findings, through our Free Communication and Poster presentation sessions. For more information regarding relevant deadlines, please visit our congress website.

We are looking forward to meeting you in Copenhagen and interacting with you both socially and professionally.

With our best wishes

Prof. Masatoshi Takeda  
*Congress President*

Prof. Constantin R. Soldatos  
*Chair of the International  
Scientific Programme  
Committee*


Prof. Gregers Wegener  
*Chair of the Local  
Organising Committee*

## About WFSBP

Founded in 1974 in Buenos Aires, Argentina, the World Federation of Societies of Biological Psychiatry is a non-profit world wide organization composed of 63 National Societies of Biological Psychiatry and Individual Members representing professionals from over 70 countries.

With this multitude of countries represented in its worldwide community, the World Federation has built an international network of over 4,500 opinion leaders, the majority of which are key opinion-leaders in the practice of Biological Psychiatry.

### WFSBP members by continent



As of December 2015




### The principle objectives of WFSBP are:

- ▶ To foster and encourage scientific research and advancement in the field of Biological Psychiatry
- ▶ To improve the quality of training spanning all the biological psychiatry sciences
- ▶ To promote education and achieve the highest level of knowledge and understanding within the field
- ▶ To provide information and guidance to all institutions, societies or individuals with an interest in biological psychiatry
- ▶ To establish, build, and maintain solid collaboration with international and national organisations related to biological psychiatry

Educational activities, regional, international and world congresses, the interactive website [www.wfsbp.org](http://www.wfsbp.org), and The World Journal of Biological Psychiatry build the World Federation's portfolio and insure its worldwide influence. The development of worldwide treatment guidelines is one of WFSBP's main areas of international leadership.

Year after year, more and more professionals choose to join the World Federation's Biological Psychiatry arena and enjoy its exclusive educational and networking opportunities. In the coming years WFSBP is looking forward to welcoming over 15 new eminent member societies from different parts of the world.

### WFSBP members by field of activity:



## About the WFSBP Congress 2017

### CONGRESS ADMINISTRATION

The 13<sup>th</sup> World Congress of Biological Psychiatry will be organised by the World Federation of Societies of Biological Psychiatry (WFSBP)

#### WFSBP EXECUTIVE COMMITTEE

**President (2015 – 2019)**

Masatoshi Takeda, Japan

**Vice President (2013 – 2017)**

Tudor Udristoiu, Romania

**Past President (2015 – 2017)**

Constantin R. Soldatos, Greece

**Secretary (2013 – 2017)**

Lakshmi N. Yatham, Canada

**Treasurer (2013 – 2017)**

Martin Hatzinger, Switzerland

**Vice Secretary (2013 – 2017)**

Ladislav Hosak,  
Czech Republic

**Vice Treasurer (2013 – 2017)**

Victoria Valdez, Ecuador

#### INTERNATIONAL SCIENTIFIC PROGRAMME COMMITTEE (ISPC)

**Chair**

Constantin R. Soldatos, Greece

**Vice Chairs**

Peter Falkai, Germany  
Lakshmi Yatham, Canada

**Deputy Chairs**

Dimitris Dikeos, Greece  
Yoshio Hirayasu, Japan  
Tudor Udristoiu, Romania

**Secretary**

Georgios Kiosterakis, Greece

**Members of ISPC**

G. Alexopoulos, USA\*

C. A. Altamura, Italy\*

C. Arango, Spain

E. Baca Garcia, Spain

M. Bauer, Germany\*

E. Belfort, Venezuela

A. Benyamina, France

M. Berk, Australia\*

J. Bobes, Spain

A. Bozkurt, Cyprus

N. Boutros, USA

C. L. Bowden, USA

P. Boyer, France

J. Bradford, Canada

P. Brambilla, Italy

M. Bras, Croatia

M. S. Buchsbaum, USA

A. Burns, UK

R. Castilla-Puentes, USA\*

D. Castle, Australia\*

E. Ceskova, Czech Republic\*

M. Cetkovich-Bakmas, Argentina

Y. Hwa Chou, Taiwan\*

H. Correa, Brazil\*

P. Cosyns, Belgium

P. Courtet, France\*

B. Dean, Australia\*

J. de Buitelaar, The Netherlands

M. Dierick, Belgium

B. Dubois, France

K. Fountoulakis, Greece\*

S. Frangou, UK

W. Gaebel, Germany

F. D. Garcia, Brazil\*

W. F. Gattaz, Brazil

P. Gejman, USA

A. Germanavicious, Lithuania

M. George, USA\*

A. H. Glassman, USA

B. Glenthøj, Denmark

G. M. Goodwin, UK

D. Gorelick, USA

P. Gorwood, France\*

A. Grace, USA\*

H. Grunze, UK\*

G. Hajak, Germany

A. Halaris, USA\*

A. Hasan, Germany

S. Heckers, USA

C. Hiemke, Germany

E. Hollander, USA

E. Holsboer-Trachsler, Switzerland\*

W. G. Honer, Canada

J. Horacek, Czech Republic

A. Jablensky, Australia

R. Kahn, The Netherlands

J. Kane, USA

S. Kanba, Japan\*

T. Kato, Japan

C. Katona, UK

W. Kaye, USA

J. Kennedy, Canada\*

L. Konopka, USA

H. R. Kranzler, USA\*

C. Krieg, Germany

T. Kudo, Japan

J. Soo Kwon, Korea

S. Lamy, France

R. Lanzenberger, Austria\*

V. Larach, Chile

M. Leboyer, France

M.S. Lee, Korea\*

M. Lejoyeux, France

B. Leonard, Ireland\*

Y. Levkovitz, Israel

A. Lopez Mato, Argentina\*

C. Lyketsos, USA

\* Special correspondents of ISC Core Group



## About the WFSBP Congress 2017

R. McCarley, USA  
P. Mc Gorry, Australia  
P. Mc Guire, UK  
M. Maes, Belgium\*  
A. Malafosse, Switzerland  
J.-L. Martinot, France  
V. Matei, Romania\*  
H. Mayberg, USA  
H. Y. Meltzer, USA  
A. Meyer-Lindenberg, Germany  
A. Kant Mital, India  
E. Mohan Das, India  
N. Müller, Germany  
T. Murai, Japan\*  
Z. Nahas, Lebanon  
D. Nutt, UK  
J. Ospina-Duque, Colombia\*  
N. Ozaki, Japan  
C. Pantelis, Australia\*  
G. Papadimitriou, Greece  
T. Paparrigopoulos, Greece\*  
G. Parker, Australia  
L. Pezewas, Austria  
O. Pogarell, Germany  
S. G. Potkin, USA  
R. Post, USA\*  
M. Rapaport, USA  
M.S. Reddy, India\*  
E. Richelson, USA  
P. Riederer, Germany  
D. Rujescu, Germany  
R. Rupprecht, Germany  
J. Rybakowski, Poland  
H. Sackeim, USA  
T. Saito, Japan  
P. Salgado Pineda, Spain  
M. Sarchiapone, Italy  
T. Schlaepfer, Germany\*  
A. Schmitt, Germany  
L. Schneider, USA  
C. Schulz, USA  
T. G. Schulze, Germany\*  
S. Seedat, South Africa\*  
E. Seifritz, Switzerland  
A. Serretti, Italy\*  
E. Serfaty, Argentina  
W. W. Shen, Taiwan

L. Siever, USA  
D. St. Clair, UK  
N. Stefanis, Greece\*  
J. Steiner, Germany  
T. Suhara, Japan  
M. Taleb, France/Algeria  
T. Taneli, USA  
J. Tellez-Vargas, Colombia  
J. Treasure, UK  
N. A. Uranova, Russia  
P. Udomratn, Thailand\*  
I. Udristoiu, Romania\*  
W. van den Brink, The Netherlands\*  
J. van Os, The Netherlands  
D. Velakoulis, Australia\*  
N. Venizelos, Sweden\*  
E. Vieta, Spain\*  
J. Waddington, Ireland  
A. Weinstein Israel  
P. Whybrow, USA  
X. Yu, China  
M. Zanarini, USA  
Y. Zervas, Greece\*  
J. Zohar, Israel

### HONORARY COMMITTEE (HC)

Jules Angst, Switzerland  
Jose Luis Ayuso, Spain  
Jorge Ciprian-Ollivier, Argentina  
Jorge Alberto Costa e Silva, Brazil  
Tetsuo Fukuda, Japan  
Gerardo Heinze, Mexico  
Carlos Roberto Hojaij, Brazil  
Florian Holsboer, Germany  
Siegfried Kasper, Austria  
Jeffrey Lieberman, USA  
Julien Mendlewicz, Belgium  
Hans-Jürgen Möller, Germany  
Robin Murray, UK  
Ahmed Okasha, Egypt  
Mitsumoto Sato, Japan  
Norman Sartorius, Switzerland  
Göran Sedvall, Sweden  
Costas Stefanis, Greece  
Florence Thibaut, France  
Michael Trimble, UK

### NATIONAL PRESIDENTS

A. Corrales, Argentina  
A. Boyajyan, Armenia  
C. Geretsegger, Austria  
S. Claes, Belgium  
N. D. Noya-Tapia, Bolivia  
A. Kucukalic, Bosnia-Herzegovina  
A. Marcolin, Brazil  
O. Atanasova Mikova-Demireva, Bulgaria  
R. W. Lam, Canada  
E. Olea, Chile  
C. Gutierrez, Columbia  
R. Castro, Costa Rica  
M. Jakovljevic, Croatia  
L. Hosak, Czech Republic  
G. Wegener, Denmark  
F. Solis de Mendez, Dominican Republic  
M. Meneses-Guevara, Ecuador  
A. Okasha, Egypt  
M. Meija Pena, El Salvador  
J. Harro, Estonia  
P. Courtet, France  
S. Herpertz, Germany  
C. R. Soldatos, Greece  
H. Soto Chavez, Guatemala  
M. Aguilar Lopez, Honduras  
S.-W. Tang, Hong Kong  
C. Banki, Hungary  
R. Nagpal, India  
A. J. Tanra, Indonesia  
D. Gothelf, Israel  
M. Maj, Italy  
T. Nishikawa, Japan  
M. Assimov, Kazakhstan  
C. Uk Lee, Korea  
B. Kupca, Latvia  
C. Baddoura, Libanon  
J. Neveranskas, Lithuania  
B. Stefanovski, Macedonia  
S. Krishnaswamy, Malaysia  
D. Moussaoui, Morocco  
G. Villanueva Colin, Mexico  
H. Lovdahl, Norway  
M. Amin, Pakistan  
G. Da Costa, Panama

\* Special correspondents of ISC Core Group

## About the WFSBP Congress 2017 / Colour Legend

L. Villalba, Paraguay  
 E. Galli, Peru  
 A. Wichniak, Poland  
 J. Relvas, Portugal  
 T. Udristoiu, Romania  
 S. Mosolov, Russia  
 N. Maric Bojovic, Serbia  
 L. Vavrusova, Slovakia  
 S. Seedat, South Africa  
 M. Bernardo, Spain  
 M. Ramklint, Sweden  
 M. Hatzinger, Switzerland  
 Ch.-Y. Liu, Taiwan  
 P. Udomratn, Thailand  
 B. Taneli, Turkey  
 A. V. Kalueff, Ukraine  
 G. Bouza, Uruguay  
 J. Ibáñez-Domínguez, Venezuela

### CHAIRS OF THE LOCAL ORGANISING COMMITTEE (LOC)

#### Chair

Gregers Wegener, Denmark

#### Deputy Chairs

Ida Hageman, Denmark  
 Søren Dinesen Østergaard, Denmark

### Members of LOC

Kjeld Andersen, Denmark  
 Ole A. Andreassen, Norway  
 Lone Baandrup, Denmark  
 Per Bech, Denmark  
 Nils Bilenberg, Denmark  
 Bjørn Ebdrup, Denmark  
 Jesper Ekelund, Finland  
 Anders Fink-Jensen, Denmark  
 Birte Glenthøj, Denmark  
 Simon Glerup, Denmark  
 Jaanus Harro, Estonia  
 Torsten Bjørn Jacobsen, Denmark  
 Martin Balslev Jørgensen, Denmark  
 Olli Kampman, Finland  
 Lars Kessing, Denmark  
 Gitte Moos Knudsen, Denmark  
 Rasmus Licht, Denmark  
 Pall Mathiasson, Iceland  
 Tanja Michel, Denmark  
 Thomas Middelboe, Denmark  
 Ole Mors, Denmark  
 Merete Nordentoft, Denmark  
 Kerstin Plessen, Denmark  
 Andreas Reif, Germany  
 Dan Rujescu, Germany  
 Bo Söderpalm, Sweden  
 Per Hove Thomsen, Denmark  
 Jari Tiihonen, Sweden  
 Anders Tingström, Sweden  
 Poul Videbech, Denmark  
 Thomas Werge, Denmark

### CONGRESS AMBASSADORS

Carlo Altamura, Italy  
 Ajit Avasthi, India  
 Charles Baddoura, Libanon  
 Robert Belmaker, Israel  
 Enrique Galli, Peru  
 Peter Gaszner, Hungary  
 Bai Han, China  
 Gerhard Heinze, Mexico  
 Nick Kates, Canada  
 Donatella Marazziti, Italy  
 Giorgio Racagni, Italy  
 M.S. Reddy, India  
 Pedro Ruiz, USA  
 Janusz Rybakowski, Poland  
 Dan Stein, South Africa  
 Andi J. Tanra, Indonesia  
 Si Tian-Mei, China  
 Eduard Vieta, Spain  
 Shigeto Yamawaki, Japan  
 Yukio Yoneda, Japan  
 Allan Young, UK

### COLOUR CODES OF SESSIONS (PRELIMINARY SCIENTIFIC PROGRAMME, PAGES 8 – 38)

<b>OP</b>	Opening Lecture
<b>PL</b>	Plenary Lectures
<b>D</b>	Debates

<b>TFS</b>	Task Force Symposia
<b>TFW</b>	Task Force Workshops
<b>S</b>	Symposia

<b>WS</b>	Workshops
<b>FC</b>	Free Communications
<b>SA</b>	Satellite Symposia

## Preliminary Scientific Programme Schedule / Sunday, 18 June 2017

8:30	<b>S-01</b> Towards novel rapid-acting antidepressants	<b>S-02</b> Psychiatric services in emergency departments: Challenges and solutions	<b>S-03</b> Dissecting the role of the neurotrophin Brain Derived Neurotrophic Factor in cocaine addiction: Clues from clinical and preclinical studies	<b>WS-01</b> Initiatives from the Spanish Society of Biological Psychiatry: From evidence to experience	<b>Free Communications</b>
9:00					
9:30					
10:00					
10:30	<b>S-04</b> Pathways of neuroprogression in Bipolar Disorder (BP)	<b>S-05</b> Extracellular vesicles in neuropsychiatric diseases: Basic mechanisms and biomarkers	<b>S-06</b> Drug addiction and GPCR heteroreceptor complexes: What goes wrong in receptor plasticity as addiction develops?	<b>WS-02</b> New investigations on the relationship between working memory and ADHD	<b>Free Communications</b>
11:00					
11:30					
12:00					
12:30	<b>S-07</b> Social cognition and neuronal correlates in patients with schizophrenia	<b>S-08</b> Inflammation markers of peripheral blood in depression spectrum	<b>Satellite Symposia</b>		<b>Free Communications</b>
13:00					
13:30					
14:00					
14:30	<b>S-09</b> Mechanisms contributing to neuroprogression in psychiatric disorders and promising interventions	<b>S-10</b> Effects and side effects of electroconvulsive therapy	<b>S-11</b> Abnormal neurogenesis in schizophrenia	<b>S-12</b> New approaches into diagnosis and treatment of psychotic Bipolar Disorder (BP)	<b>Free Communications</b>
15:00					
15:30					
16:00					
16:30	<b>S-13</b> Biomarkers for early diagnosis of Alzheimer's Disease (AD) and other neurodegenerating diseases: Advantages and limitations	<b>Satellite Symposia</b>			<b>Free Communications</b>
17:00					
17:30					
18:00	<b>Opening Ceremony 18:00 – 19:00</b>				
18:30	(incl. <b>OP-01</b> The microbiome-gut-brain axis: A key regulator of brain & behaviour across the lifespan)				
	<b>Registration Counter</b> 07:30 – 19:00				



## Monday, 19 June 2017 / Preliminary Scientific Programme Schedule

8:30	<b>S-14</b> Problematic sexual behaviors: Diagnostic, categorical, epidemiological, imaging, psychopathological and treatment considerations	<b>S-15</b> Posttraumatic Stress Disorder (PTSD) and gender	<b>S-16</b> The elephant in the room: The role of glial cells in psychiatric disorders	<b>S-17</b> Psychosis is disrespectful to diagnostic boundaries: Nosological and pathobiological implications of psychoses beyond ...	<b>S-18</b> Epigenetic modification, effect of early life stress, and signaling mechanisms in suicide	<b>S-19</b> Psychedelics: Mechanisms and applications in psychiatry	<b>S-20</b> Affective and psychotic psychopathology from pregnancy to early adulthood: The dynamic developmental interplay ...	<b>Free Communications</b>	
9:00									
9:30									
10:00									
10:30	<b>Plenary Lecture</b> <b>PL-01</b> Drug discovery in neuroscience: Promises, barriers and opportunities								
11:00									
11:30	<b>D-01</b> Antidepressants are effective for treating acute bipolar depression	<b>TFS-01</b> Therapeutic drug monitoring, pharmacogenetics and brain imaging methods as tools for optimizing pharmacotherapy in psychiatry	<b>S-21</b> Measurement-based psychiatry: Toward rating scale-based assessments in the real world	<b>S-22</b> Dissecting the shared and non-shared biological features in schizophrenia and autism spectrum disorder	<b>S-23</b> Combining cognitive remediation with brain imaging techniques: Evidence for neural changes or neuroplasticity?	<b>WS-03</b> Current status of electroconvulsive therapy in the treatment of major psychiatric disorders	<b>S-24</b> Serotonin and anxiety disorders: Recent evidences from neuroimaging studies	<b>Free Communications</b>	
12:00									
12:30									
13:00									
13:30									
14:00	<b>Satellite Symposia</b>								
14:30									
15:00	<b>S-25</b> tDCS: From research to clinical practice	<b>TFS-02</b> Post-mortem findings across psychiatric disorders and their association with cognitive symptoms	<b>TFW-01</b> Workshop of the WFSBP Task Force on Genetics: Focus on pharmacogenomics	<b>S-26</b> Into novel drugs for depression	<b>S-27</b> Beyond unitary models of psychosis: Confronting complex etiology and dimensionality	<b>WS-04</b> Rethinking depression in the Century XXI: Where are we now in biological psychiatry?	<b>S-28</b> Wake and sleep electroencephalogram provide biomarkers of depression	<b>Free Communications</b>	
15:30									
16:00									
16:30									
17:00	<b>S-29</b> Autism spectrum disorders in adults – from the clinical phenotype to the underlying neurobiology – novell technics such ...	<b>TFS-03</b> Update biomarkers in psychiatry	<b>Satellite Symposia</b>					<b>Free Communications</b>	
17:30									
18:00									
18:30									
<b>Registration Counter</b> 08:00 – 18:30				<b>Poster Exhibition</b> 09:00 – 17:00				<b>Technical Exhibition</b> 09:00 – 17:00	



## Preliminary Scientific Programme Schedule / Tuesday, 20 June 2017

8:30	<b>S-30</b> Recent insights in schizophrenia pathophysiology and treatments	<b>S-31</b> Duration of untreated psychosis: From neuroimaging to clinical trials	<b>S-32</b> New perspectives on transcranial magnetic stimulation in psychiatric disorders	<b>S-33</b> Epigenetic biomarkers for the diagnosis of mood disorders	<b>S-34</b> Sex hormones and their wide-ranging effects on psychopathology	<b>WS-05</b> Gesture as window to psychosis pathobiology: From aberrant body experience to social interaction	<b>S-35</b> New insights into the neurobiology and treatment aspects of obsessive compulsive disorder comorbid with schizophrenia and bipolar ...	<b>Free Communications</b>
9:00								
9:30								
10:00								
10:30	<b>Plenary Lecture</b> <b>PL-02</b> Novel treatments in mood disorders: Molecular mechanisms and clinical applications							
11:00								<b>Free Communications</b>
11:30	<b>D-02</b> The Research Domain Criteria (RDoC) can create a new kind of taxonomy holding greater promise compared to the traditional ...	<b>TFS-04</b> Sleep in depression and cognition – from research to clinical practice	<b>S-36</b> The role of the nucleus accumbens in psychiatry	<b>S-37</b> Neurobiologic imaging studies of mood disorders, neurogenetics and antidepressant action with positron emission tomography	<b>S-38</b> Treatment resistant schizophrenia: Definitions, psychobiology and clinical treatment	<b>WS-06</b> Neurobiology of suicidal behaviour		
12:00								
12:30								
13:00								
13:30								
14:00	<b>Satellite Symposia</b>							
14:30								
15:00	<b>WS-07</b> Merging evidence and clinical practice in management of depression: The CANMAT experience	<b>TFS-05</b> Biomarkers for schizophrenia: From molecules to brain function. A consensus of the WFSBP Task Force on biological markers	<b>TFW-02</b> WFSBP Consensus on the management of agitation in psychiatry	<b>S-39</b> Current research on the use of cannabinoids	<b>S-40</b> Alzheimer's Disease (AD) pathophysiology, prevention and treatment strategies: Where we stand and where we go?	<b>WS-08</b> Functional neuroanatomy of hallucinations	<b>S-41</b> Electroconvulsive therapy for depression – optimising treatment and maintaining recovery	<b>Free Communications</b>
15:30								
16:00								
16:30								
17:00	<b>S-42</b> Neuroepigenetic approaches to assess disease risk, mechanism and treatment	<b>TFS-06</b> Electroconvulsive therapy: Beyond depression	<b>Satellite Symposia</b>					<b>Free Communications</b>
17:30								
18:00								
18:30								
	<b>Registration Counter</b> 08:00 – 18:30			<b>Poster Exhibition</b> 09:00 – 17:00			<b>Technical Exhibition</b> 09:00 – 17:00	

## Wednesday, 20 June 2017 / Preliminary Scientific Programme Schedule

8:30	<b>S-43</b> Novel approaches in mechanisms of action of antidepressant treatment	<b>S-44</b> Cannabinoid Receptor (CBR) gene variations in neuropsychiatric disorders	<b>S-45</b> Behavioral Addictions: Diagnosis, co-morbidity and neurobiology	<b>S-46</b> Neurobiology and psychopharmacology of aggressive behaviour: Where are we?	<b>S-47</b> Catecholamines, anhedonia and depression	<b>Free Communications</b>		
9:00								
9:30								
10:00								
10:30	<b>Plenary Lecture</b> <b>PL-03</b> Epigenetic consequences of early adversity: Implications for psychiatric disorders							
11:00								
11:30	<b>D-03</b> Deep brain stimulation is a worthwhile treatment method in psychiatry	<b>TFS-07</b> Enhancing the role of primary care in looking after people with mental health problems: A new position paper from the Collaborative ...	<b>S-48</b> Pharmacogenetics of drug defense and neuroprotection: From the Neandertal to the modern humans	<b>S-49</b> Evidence-based guidelines for treatment of major depressive disorder: Contrasting views across the world	<b>S-50</b> Real time assessment of psychopathology and behavior in Bipolar Disorder (BP) using e-mental health technologies	<b>WS-09</b> Schizophrenia research in Chile	<b>Free Communications</b>	
12:00								
12:30								
13:00								
13:30								
14:00	<b>Satellite Symposia</b>							
14:30								
15:00	<b>S-51</b> Advances in biomarker development for neurostimulation	<b>TFS-08</b> Men's mental health: Contemporary aspects	<b>TFW-03</b> WFSBP Treatment Guideline Session: Do bipolar mixed states merit a treatment guideline on its own?	<b>S-52</b> The G protein coupled receptors as a target for psychotropic drugs	<b>S-53</b> Suicidal behavior: Neurobiological and genetic determinants	<b>WS-10</b> Evidence for brain stimulation methods in schizophrenia	<b>Free Communications</b>	
15:30								
16:00								
16:30								
17:00	<b>S-54</b> Lithium as a neuroprotective agent: When and how?	<b>TFS-09</b> Providing acute inpatient care for children, adolescents and young adults from a men's mental health perspective: Focus on ...	<b>S-55</b> Rediscovering Lithium	<b>Satellite Symposia</b>			<b>Free Communications</b>	
17:30								
18:00								
18:30								
Registration Counter 08:00 – 18:30				Poster Exhibition 09:00 – 17:00		Technical Exhibition 09:00 – 17:00		



# Preliminary Scientific Programme Schedule / Thursday, 22 June 2017

8:30	<b>S-56</b> Clinical effects and neural mechanisms of electro-convulsive therapy in major depression and schizophrenia	<b>S-57</b> Causes and consequences of inflammation in Bipolar Disorder (BP)	<b>S-58</b> Novel therapeutics for neurodegenerative disorders	<b>S-59</b> The relevance of Neuregulin1-ErbB4 signaling for neuropsychiatric pathomechanisms: Converging insights from mouse ...	<b>S-60</b> Multi-omics and psychiatry: The missing molecular link	<b>S-61</b> Suicide: Aspects that burn	<b>Free Communications</b>
9:00							
9:30							
10:00	<b>Plenary Lecture</b> <b>PL-04</b> Lithium in mood disorders including a homage to Danish contribution						
10:30							
11:00	<b>S-62</b> Innovative approaches in suicide research	<b>S-63</b> Atypical neurotransmitters in psychiatry: Relevance for future therapeutics	<b>S-64</b> Operationalizing the dysconnection syndrome: Translational approaches reveal brain network dysfunction in schizophrenia	<b>S-65</b> Cell-type specific epigenetic, proteomic and gene expression signatures in schizophrenia: New findings from post-mortem ...	<b>S-66</b> NMDA receptor antagonists in psychiatry	<b>S-67</b> Spectrum of Mood Disorders (MD): Where is the place for mixed states?	<b>Free Communications</b>
11:30							
12:00							
12:30	<b>Satellite Symposia</b>						
13:00							
13:30							
14:00							
14:30	<b>Closing Ceremony</b>						
15:00							
15:30							
16:00							
16:30	<b>Registration Counter</b> 08:00 – 17:30						
17:00							
17:30							
18:00							
18:30	<b>Poster Exhibition</b> 09:00 – 17:00						

## Opening Lecture, Plenary Lectures, Debates / Preliminary Scientific Programme

### Opening Lecture

#### ► Sunday, 18 June 2017

##### OP-01

18:00–19:00

#### **The microbiome-gut-brain axis: A key regulator of brain & behaviour across the lifespan**

*Chair:* Masatoshi Takeda, Japan

*Speaker:* John F. Cryan, Ireland

### Plenary Lectures

#### ► Monday, 19 June 2017

##### PL-01

10:15–11:00

#### **Drug discovery in neuroscience: Promises, barriers and opportunities**

*Chair:* Lakshmi Yatham, Canada

*Speaker:* Husseini Manji, USA

#### ► Tuesday, 20 June 2017

##### PL-02

10:15–11:00

#### **Novel treatments in mood disorders: Molecular mechanisms and clinical applications**

*Chair:* Gregers Wegener, Denmark

*Speaker:* Carlos Zarate, USA

#### ► Wednesday, 21 June 2017

##### PL-03

10:15–11:00

#### **Epigenetic consequences of early adversity: Implications for psychiatric disorders**

*Chair:* Constantin R. Soldatos, Greece

*Speaker:* Elisabeth Binder, Germany

#### ► Thursday, 22 June 2017

##### PL-04

10:15–11:00

#### **Lithium in mood disorders including a homage to Danish contribution**

*Chair:* Tudor Udristoiu, Romania

*Speaker:* Janusz Rybakowski, Poland

### Debates

#### ► Monday, 19 June 2017

##### D-01

11:15–12:45

#### **Antidepressants are effective for treating acute bipolar depression**

*Chair:* Lakshmi Yatham, Canada

*Proponent:* Glenda MacQueen, Canada

*Opponent:* Robert Post, USA

#### ► Tuesday, 20 June 2017

##### D-02

11:15–12:45

#### **The Research Domain Criteria (RDoC) can create a new kind of taxonomy holding greater promise compared to the traditional Nosological Classification Systems in psychiatry**

*Chair:* Sabine Herpertz, Germany

*Proponent:* Andreas Heinz, German

*Opponent:* Henning Saß, Germany

#### ► Wednesday, 21 June 2017

##### D-03

11:15–12:45

#### **Deep brain stimulation is a worthwhile treatment method in psychiatry**

*Chair:* Gregers Wegener, Denmark

*Proponent:* Thomas Schlöpfer, Germany

*Opponent:* Marwan Hariz, United Kingdom

## Preliminary Scientific Programme / WFSBP Task Force Symposia

### WFSBP Task Force Symposia

► **Monday, 19 June 2017**

#### T51: PSYCHOPHARMACOLOGY

##### TFS-01

11:15–12:45

**Therapeutic drug monitoring, pharmacogenetics and brain imaging methods as tools for optimizing pharmacotherapy in psychiatry**

Chair: *Chin B. Eap, Switzerland*

Co-Chair: *Christoph Hiemke, Germany*

##### TFS-01-001

**Pharmacogenetics in psychiatry**

*Chin B. Eap, Switzerland*

##### TFS-01-002

**Therapeutic drug monitoring in psychiatry**

*Christoph Hiemke, Germany*

##### TFS-01-003

**Brain imaging in psychiatry**

*Gerhard Gründer, Germany*

##### TFS-01-004

**Strategies for the implementation of genetic biomarkers in clinical practice**

*Daniel Müller, Canada*

#### T24: NEUROPATHOLOGY

##### TFS-02

15:00–16:30

**Post-mortem findings across psychiatric disorders and their association with cognitive symptoms**

Chair: *Andrea Schmitt, Germany*

Co-Chair: *Johann Steiner, Germany*

##### TFS-02-001

**Alterations in hippocampal oligodendrocyte and neuron number in patients with schizophrenia, Bipolar Disorder (BP) and major depression**

*Peter Falkai, Germany*

##### TFS-02-002

**GABAergic system impairment in the hippocampus and superior temporal gyrus of patients with paranoid schizophrenia**

*Johann Steiner, Germany*

##### TFS-02-003

**Presynaptic contributions to cognitive reserve**

*William Honer, Canada*

##### TFS-02-004

**Different changes in cortical muscarinic receptors in psychiatric and neurological disorders**

*Brian Dean, Australia*

#### T22: MOLECULAR NEUROBIOLOGY

##### TFS-03

17:00–18:30

**Update biomarkers in psychiatry**

Chair: *Peter Riederer, Germany*

Co-Chair: *Peter Falkai, Germany*

##### TFS-03-001

**Biomarkers for schizophrenia**

*Florence Thibaut, France*

##### TFS-03-002

**Biological marker in alcoholism**

*Toshikazu Saito, Japan*

##### TFS-03-003

**Specificity of biomarkers for OCD/ADHD**

*Edna Grünblatt, Switzerland*

##### TFS-03-004

**Specificity of biomarkers for anxiety**

*Borwin Bandelow, Germany*

► **Tuesday, 20 June 2017**

#### T45: SLEEP DISORDERS: BASIC / CLINICAL

##### TFS-04

11:15–12:45

**Sleep in depression and cognition – from research to clinical practice**

Chair: *Edith Holsboer-Trachsler, Switzerland*

Co-Chair: *Birendra N. Mallick, India*

##### TFS-04-001

**Sleep as biomarker: Predictor of emotional regulation and depression**

*Martin Hatzinger, Switzerland*

##### TFS-04-002

**Sleep in dementia: A biomarker of cognition?**

*Dimitris Dikeos, Greece*

##### TFS-04-003

**Sleep and synaptic dysfunction in depression**

*Anne Eckert, Switzerland*

##### TFS-04-004

**REM sleep and prevention of neurodegeneration: Role of noradrenaline**

*Birendra N. Mallick, India*

## WFSBP Task Force Symposia / Preliminary Scientific Programme

### T43: SCHIZOPHRENIA: BASIC / CLINICAL

#### TFS-05

15:00–16:30

**Biomarkers for schizophrenia: From molecules to brain function. A consensus of the WFSBP Task Force on biological markers**

*Chair:* Andrea Schmitt, Germany

*Co-Chair:* Daniel Martins de Souza, Brazil

#### TFS-05-001

**Genetic biomarkers**

*Dan Rujescu, Germany*

#### TFS-05-002

**Neuroimaging biomarkers**

*Nikolaos Koutsouleris, Germany*

#### TFS-05-003

**Molecular biomarkers**

*Daniel Martins de Souza, Brazil*

#### TFS-05-004

**Cognition biomarkers**

*Peter Falkai, Germany*

### T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

#### TFS-06

17:00–18:30

**Electroconvulsive therapy: Beyond depression**

*Chair:* Georgios Petrides, USA

*Co-Chair:* William McDonald, USA

#### TFS-06-001

**ECT for the treatment of catatonia**

*Tom Bolwig, Denmark*

#### TFS-06-002

**ECT in autism spectrum disorders: Catatonia and beyond**

*Lee Wachtel, USA*

#### TFS-06-003

**ECT for agitation in elderly patients with dementia**

*Adriana Hermida, USA*

#### TFS-06-004

**ECT-related mortality rates**

*Søren Dinesen Østergaard, Denmark*

### ► Wednesday, 21 June 2017

### T20: LIAISON PSYCHIATRY

#### TFS-07

11:15–12:45

**Enhancing the role of primary care in looking after people with mental health problems: A new position paper from the Collaborative Care Task Force of the WFSBP**

*Chair:* Nick Kates, Canada

#### TFS-07-001

**Improving primary mental health care – Definitions, models, principles and challenges**

*Nick Kates, Canada*

#### TFS-07-002

**Integrating mental health services within primary care settings**

*Henrikje Klasen, The Netherlands*

#### TFS-07-003

**The role of the family physician in delivering mental health care**

*Torleif Ruud, Norway*

#### TFS-07-004

**Capacity building, training and adapting the approach for different countries**

*Nick Kates, Canada*

### T51: MEN'S MENTAL HEALTH

#### TFS-08

15:00–16:30

**Men's mental health: Contemporary aspects**

*Chair:* Leo Sher, USA

*Co-Chair:* Timothy Rice, USA

#### TFS-08-001

**Future research and clinical directions in the field of men's mental health**

*Leo Sher, USA*

#### TFS-08-002

**Towards a neuropsychiatric model of disruptive behavior disorders in boys and young men: Developmental deficits in the emotion regulation system, their origin, and their therapeutic address**

*Timothy Rice, USA*

#### TFS-08-003

**Sex differences in addictive disorder and its clinical connotation**

*Shih-Ku Lin, Taiwan*

## Preliminary Scientific Programme / WFSBP Task Force Symposia and Workshops

### TFS-08-004

#### Sex differences in early predictors of adult personality and intelligence

*Trine Flensburg-Madsen, Denmark*

### T50: VIOLENCE: BASIC/CLINICAL

#### TFS-09

17:00–18:30

#### Providing acute inpatient care for children, adolescents and young adults from a men's mental health perspective: Focus on violence reduction

*Chair: Pilar Trelles, USA*

*Co-Chair: Lesha Shah, USA*

### TFS-09-001

#### Brain development: A focus on normal male development and psychopathology

*Pilar Trelles, USA*

### TFS-09-002

#### Asking for the IM: What to do when the disruptive male child appears to seek punishment

*Timothy Rice, USA*

### TFS-09-003

#### Agression in adolescence

*Lesha Shah, USA*

### TFS-09-004

#### Violent and suicidal behavior among young male veterans on an inpatient psychiatric unit

*Leo Sher, USA*

### TFW-01-003

#### Whole exom sequencing reveals risk factors in treatment resistant depression

*Alessandro Serretti, Italy*

### TFW-01-004

#### Pharmacogenetic discoveries and applications in psychiatric populations

*Jim Kennedy, Canada*

### ► Tuesday, 20 June 2017

### T13: EMERGENCY PSYCHIATRY

#### TFW-02

15:00–16:30

#### WFSBP consensus on the management of agitation in psychiatry

*Chair: Siegfried Kasper, Austria*

*Co-Chair: Eduard Vieta, Spain*

### TFW-02-001

#### Agitation: Causes and differential diagnosis

*Marina Garriga, Spain*

### TFW-02-002

#### Agitation in schizophrenia

*Dieter Naber, Germany*

### TFW-02-003

#### Agitation in Bipolar Disorder (BP)

*Lakshmi Yatham, Canada*

### TFW-02-004

#### WFSBP Consensus on agitation in psychiatry

*Eduard Vieta, Spain*

### ► Wednesday, 21 June 2017

### T6: BIPOLAR DISORDERS: BASIC/CLINICAL

#### TFW-03

15:00–16:30

#### WFSBP Treatment Guideline Session: Do bipolar mixed states merit a treatment guideline on its own?

*Chair: Siegfried Kasper, Austria*

*Co-Chair: Heinz Grunze, United Kingdom*

### TFW-03-001

#### Clinical manifestations of bipolar mixed states-epidemiological and clinical research

*Jean-Michel Azorin, France*

### TFW-03-002

#### The changing concept of mixed states over time: DSM5 broadening and downgrading at the same time

*Eduard Vieta, Spain*

## WFSBP Task Force Workshops

### ► Monday, 19 June 2017

### T32: PHARMACOGENETICS

#### TFW-01

15:00–16:30

#### Workshop of the WFSBP Task Force on genetics: Focus on pharmacogenomics

*Chair: Dan Rujescu, Germany*

*Co-Chair: Jim Kennedy, Canada*

### TFW-01-001

#### Pharmacogenetics in schizophrenia

*Rainald Mössner, Germany*

### TFW-01-002

#### Largest genome wide association study on agranulocytosis under Clozapine

*Dan Rujescu, Germany*



WFSBP Task Force Workshops, Symposia / Preliminary Scientific Programme

**TFW-03-003**

**The WFSBP Treatment guideline for mixed states-evidence and recommendations**

*Heinz Grunze, United Kingdom*

**TFW-03-004**

**What the CINP guideline recommends in mixed states**

*Konstantinos Fountoulakis, Greece*

**Symposia**

► **Sunday, 18 June 2017**

**T2: ANTIDEPRESSANTS: BASIC / CLINICAL**

**S-01**

08:30–10:00

**Towards novel rapid-acting antidepressants**

*Chair: Tomi Rantamäki, Finland*

*Co-Chair: Gregers Wegener, Denmark*

**S-01-001**

**Rapid acting antidepressants in chronic pain**

*Ipek Yalcin, France*

**S-01-002**

**Morphological and structural alterations following rapid acting antidepressants**

*Gregers Wegener, Denmark*

**S-01-003**

**Antidepressant potential of cannabidiol: Preclinical evidence**

*Sâmia Joca, Brazil*

**S-01-004**

**Anesthetics as rapid-acting antidepressants**

*Tomi Rantamäki, Finland*

**T20: LIAISON PSYCHIATRY**

**S-02**

08:30–10:00

**Psychiatric services in emergency departments: Challenges and solutions**

*Chair: Ruby Castilla-Puentes, USA*

*Co-Chair: Tatiana Falcone, USA*

**S-02-001**

**Psychiatric consultations in rural general hospitals – Latinos vs. Anglos**

*Bernardo Ng, USA*

**S-02-002**

**A study of insomnia and comorbid psychiatric conditions in rehabilitation clinics**

*Franklin Escobar, Colombia*

**S-02-003**

**Depression and medical comorbidity in emergency departments in Mexico**

*Ricardo Secin, Mexico*

**S-02-004**

**Self-inflicted injury in children and adolescents: A study in a tertiary care hospital in Santiago de Chile**

*Arturo Grau, Chile*

**T1: ADDICTIVE DISORDERS**

**S-03**

08:30–10:00

**Dissecting the role of the neurotrophin Brain Derived Neurotrophic Factor in cocaine addiction: Clues from clinical and preclinical studies**

*Chair: Fabio Fumagalli, Italy*

**S-03-001**

**Acute exposure to cocaine during brain development evokes depressive-like behaviors via downregulation of Brain Derived Neurotrophic Factor signaling**

*Fabio Fumagalli, Italy*

**S-03-002**

**Cocaine and orbitofrontal cortical Brain Derived Neurotrophic Factor deficiency induce habit-based decision-making: Blockade by trkB stimulation**

*Shannon Gourley, USA*

**S-03-003**

**Systemic administration of the brain-penetrant TrkB antagonist cyclothiazin-b reduces short and long access cocaine intake**

*Michel Verheij, The Netherlands*

**S-03-004**

**Brain Derived Neurotrophic Factor and cocaine in clinical samples: A useful biomarker for treatment?**

*Lisia von Diemen, Brazil*

**T6: BIPOLAR DISORDERS: BASIC / CLINICAL**

**S-04**

10:15–11:45

**Pathways of neuroprogression in Bipolar Disorder (BP)**

*Chair: Benicio Frey, Canada*

*Co-Chair: Flavio Kapczinski, Brazil*

**S-04-001**

**Indicators of risk and resilience in the high-risk offspring of bipolar parents**

*Anne Duffy, Canada*

## Preliminary Scientific Programme / Symposia

**S-04-002**

**Lithium compared to quetiapine in the maintenance phase after a first episode of mania**

*Michael Berk, Australia*

**S-04-003**

**Biological rhythms and illness progression in Bipolar Disorder (BP)**

*Benicio Frey, Canada*

**S-04-004**

**Illness trajectories and neuroprogression in Bipolar Disorder (BP)**

*Flavio Kapczinski, Brazil*

**T22: MOLECULAR NEUROBIOLOGY**
**S-05**

10:15–11:45

**Extracellular vesicles in neuropsychiatric diseases: Basic mechanisms and biomarkers**

*Chair: Takashi Kudo, Japan*

*Co-Chair: Dimitrios Kapogiannis, USA*

**S-05-001**

**Extracellular vesicles as a source of biomarkers for Alzheimer's Disease**

*Dimitrios Kapogiannis, USA*

**S-05-002**

**Tau inside neutrally-derived exosome**

*Dominic Walsh, USA*

**S-05-003**

**Mechanisms of exosome involvement in neurodegenerative diseases**

*Andrew Hill, Australia*

**S-05-004**

**Changes in exosomes proteins by the degree of stress**

*Takashi Kudo, Japan*

**T22: MOLECULAR NEUROBIOLOGY**
**S-06**

10:15–11:45

**Drug addiction and GPCR heteroreceptor complexes: What goes wrong in receptor plasticity as addiction develops?**

*Chair: Kjell Fuxe, Sweden*

*Co-Chair: Anita Hansson, Germany*

**S-06-001**

**Neurochemical mechanisms underlying goal-directed and habitual drug seeking and how these mechanisms produce compulsions: Focus on Gq-coupled glutamate receptors**

*Peter Kalivas, USA*

**S-06-002**

**Homo and heteroreceptor complexes participate in learning and memory and as an emerging target for treatment of cocaine addiction**

*Dasiel Borroto-Escuela, Sweden*

**S-06-003**

**Evidence for a role of A2A-D2 heteroreceptor complexes in cocaine addiction**

*Malgorzata Filip, Poland*

**S-06-004**

**Dopamine D4 –MOR interactions prevent nigrostriatal dopamine pathway activation by morphine: Relevance for drug addiction**

*Alicia Rivera, Spain*

**T43: SCHIZOPHRENIA: BASIC/CLINICAL**
**S-07**

12:30–14:00

**Social cognition and neuronal correlates in patients with schizophrenia**

*Chair: Gabriele Sachs, Austria*

*Co-Chair: Armida Mucci, Italy*

**S-07-001**

**Neurocognitive predictors of social cognition**

*Vijaya Lakshmi Valaparla, India*

**S-07-002**

**Emotional intelligence in patients suffering from schizophrenia and unaffected siblings**

*Alex Hofer, Austria*

**S-07-003**

**Social cognition and negative symptoms in schizophrenia: Constructs, assessment and relationships with functional outcome**

*Armida Mucci, Italy*

Symposia / Preliminary Scientific Programme

**S-07-004**

**Neurobiological correlates of the treatment of emotion processing in schizophrenia**

*Gabriele Sachs, Austria*

**T19: INFLAMMATION PSYCHIATRY**

**S-08**

12:30–14:00

**Inflammation markers of peripheral blood in depression spectrum**

*Chair: Piotr Galecki, Poland*

*Co-Chair: Angelos Halaris, USA*

**S-08-001**

**(Auto)immune biomarkers of depression and subtypes**

*Michael Maes, Thailand*

**S-08-002**

**Targeting inflammation to prevent depression**

*Michael Berk, Australia*

**S-08-003**

**Stratification of depressed patients by means of blood markers of inflammation, growth factors and kynurenine metabolites**

*Angelos Halaris, USA*

**S-08-004**

**Omega-3 fatty acids, inflammation and depression: From biological mechanisms to clinical application**

*Kuan-Pin Su, Taiwan*

**T39: PSYCHONEUROIMMUNOLOGY**

**S-09**

14:30–16:00

**Mechanisms contributing to neuroprogression in psychiatric disorders and promising interventions**

*Chair: Angelos Halaris, USA*

**S-09-001**

**Inflammatory and innate immune markers of neuroprogression in depressed and teenage suicide brain**

*Ghanshyam Pandey, USA*

**S-09-002**

**Major depression as a prelude to dementia: What is the evidence?**

*Brian Leonard, Ireland*

**S-09-003**

**Neuroimaging of microglia activation in major depression**

*Jeffrey Meyer, Canada*

**S-09-004**

**Promising neuroprotective and anti-inflammatory interventions to arrest neuroprogression**

*Angelos Halaris, USA*

**T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)**

**S-10**

14:30–16:00

**Effects and side effects of electroconvulsive therapy**

*Chair: Michael Grözinger, Germany*

*Co-Chair: Helge Frieling, Germany*

**S-10-001**

**Effects of ECT on the oxygen saturation in the frontal brain**

*Michael Grözinger, Germany*

**S-10-002**

**DNA methylation of P11/S100A10: A putative marker of response to ECT?**

*Helge Frieling, Germany*

**S-10-003**

**Electroconvulsive therapy enhances amyloid  $\beta$  1-42 in the cerebrospinal fluid of patients with major depression**

*Alexander Sartorius, Germany*

**S-10-004**

**The EFFECT-Dep Trial (ISRCTN23577151): Immediate and long-term cognitive outcomes**

*Declan McLoughlin, Ireland*

**T43: SCHIZOPHRENIA: BASIC / CLINICAL**

**S-11**

14:30–16:00

**Abnormal neurogenesis in schizophrenia**

*Chair: Dragos Inta, Germany*

*Co-Chair: Guo-Li Ming, USA*

**S-11-001**

**Modeling predisposition to schizophrenia using hiPSCs**

*Kristen Brennand, USA*

**S-11-002**

**Neurogenesis and psychiatric neurodevelopmental disorders**

*Guo-Li Ming, USA*

**S-11-003**

**Precise activation of the Reelin pathway controls dendritic maturation, synapse formation and glial ensheathment of adult-generated granule cells**

*Eduardo Soriano, Spain*

## Preliminary Scientific Programme / Symposia

**S-11-004**
**Adult neurogenesis in the striatum: Effect of psychiatric treatment**

*Dragos Inta, Germany*

**T6: BIPOLAR DISORDERS: BASIC / CLINICAL**
**S-12**

14:30–16:00

**New approaches into diagnosis and treatment of psychotic Bipolar Disorder (BP)**

*Chair: Carlo Altamura, Italy*

*Co-Chair: Allan Young, United Kingdom*

**S-12-001**
**Neuroimaging aspects of psychotic Bipolar Disorder (BP)**

*Paolo Brambilla, Italy*

**S-12-002**
**Candidate biomarkers for psychotic Bipolar Disorder (BP): The role of neuroinflammation and hormones**

*Massimiliano Buoli, Italy*

**S-12-003**
**Pharmacological treatment of psychotic Bipolar Disorder (BP)**

*Trisha Suppes, USA*

**T10: DEMENTIA: BASIC / CLINICAL**
**S-13 SYMPOSIUM**

16:30–18:00

**Biomarkers for early diagnosis of Alzheimer's Disease (AD) and other neurodegenerating diseases: Advantages and limitations**

*Chair: Piotr Lewczuk, Germany*

*Co-Chair: Henrik Zetterberg, Sweden*

**S-13-001**
**New developments in the biomarkers for Alzheimer's Disease (AD)**

*Kaj Blennow, Sweden*

**S-13-002**
**Amyloid beta 42/40 Ratio in diagnosis of AD: Do we need it?**

*Piotr Lewczuk, Germany*

**S-13-003**
**Sensitive technologies for blood biomarkers in neurodegeneration**

*Henrik Zetterberg, Sweden*

**S-13-004**
**Current diagnostic approaches in frontotemporal lobar degeneration**

*Markus Otto, Germany*

**► Monday, 19 June 2017**
**T1: ADDICTIVE DISORDERS**
**S-14**

08:30–10:00

**Problematic sexual behaviors: Diagnostic, categorical, epidemiological, imaging, psychopathological and treatment considerations**

*Chair: Marc Potenza, USA*

*Co-Chair: Florence Thibaut, France*

**S-14-001**
**Classification and clinical issues relating to hypersexuality**

*Marc Potenza, USA*

*S. Kraus*

**S-14-002**
**Sexual impulsivity, psychopathology and trauma: Gender-related differences**

*Galit Erez, Israel*

**S-14-003**
**Advances in pharmacological treatments for sex offenders**

*Florence Thibaut, France*

**S-14-004**
**Neurobiology of compulsive sexual behaviors**

*Valerie Voon, United Kingdom*

**T35: POSTTRAUMATIC STRESS: BASIC / CLINICAL**
**S-15**

08:30–10:00

**Posttraumatic Stress Disorder (PTSD) and gender**

*Chair: Hans-Jürgen Möller, German*

*Co-Chair: Victoria Valdez, Ecuador*

**S-15-001**
**Clinical issues: PTSD and gender violence**

*Victoria Valdez, Ecuador*

**S-15-002**
**Course and prognosis PTSD**

*Kayihan Oguz Karamustafa, Turkey*

**S-15-003**
**Biological aspects and PTSD**

*Soraya Seedat, South Africa*

**S-15-004**
**Genetics and PTSD**

*Sian Hermann, South Africa*

Symposia / Preliminary Scientific Programme

**T43: SCHIZOPHRENIA: BASIC / CLINICAL**

**S-16**

08:30–10:00

**The elephant in the room: The role of glial cells in psychiatric disorders**

Chair: Sabina Berretta, USA

Co-Chair: Mikhail Pletnikov, USA

**S-16-001**

**Psychiatric genetic risk factors in healthy and diseased astrocytes**

Mikhail Pletnikov, USA

**S-16-002**

**Glia-extracellular matrix interactions in the pathophysiology of schizophrenia and Bipolar Disorder (BD)**

Sabina Berretta, USA

**S-16-003**

**Abnormalities of glutamate transporter localization in severe mental illness**

Robert McCullumsmith, USA

**S-16-004**

**Evidence for neuroinflammation, gliosis and leaky brain in people with schizophrenia**

Cyndi Shannon Weickert, Australia

**T43: SCHIZOPHRENIA: BASIC / CLINICAL**

**S-17**

08:30–10:00

**Psychosis is disrespectful to diagnostic boundaries: Nosological and pathobiological implications of psychoses beyond the schizophrenia spectrum**

Chair: John Waddington, Ireland

Co-Chair: Peter Buckley, USA

**S-17-001**

**Reconciling the diversity of psychotic illness and dimensional concepts with current diagnostic algorithms**

Rajiv Tandon, USA

**S-17-002**

**Psychosis in major depressive disorder: Systematic comparisons with and beyond the schizophrenia spectrum**

John Waddington, Ireland

**S-17-003**

**Psychosis in Bipolar Disorder (BP): Genetics and relationships to paternal age**

Peter Buckley, USA

J. Waddington

**S-17-004**

**Post-stroke psychosis: Pathobiology and behavioral susceptibility**

Eileen Joyce, United Kingdom

**T49: SUICIDE: BASIC / CLINICAL**

**S-18**

08:30–10:00

**Epigenetic modification, effect of early life stress, and signaling mechanisms in suicide**

Chair: Ghanshyam Pandey, USA

Co-Chair: Victoria Arango, USA

**S-18-001**

**Impact of the early-life environment on the epigenetic regulation of the anterior cingulate gyrus**

Gustavo Turecki, Canada

**S-18-002**

**Expression and methylation of glucocorticoid receptors and FKBP5 in teenage and adult suicide**

Ghanshyam Pandey, USA

**S-18-003**

**Genome-wide epigenetic changes in suicide attempters**

Jussi Jokinen, Sweden

**S-18-004**

**5-HT1A receptor anti-apoptotic transduction pathways in suicide**

Victoria Arango, USA

**T11: DEPRESSION: BASIC / CLINICAL**

**S-19**

08:30–10:00

**Psychedelics: Mechanisms and applications in psychiatry**

Chair: Tomas Palenicek, Czech Republic

Co-Chair: Franz X. Vollenweider, Switzerland

**S-19-001**

**Role of 5-HT2A receptors in the mechanism of action of psilocybin and LSD and the treatment of affective disorders**

Franz X. Vollenweider, Switzerland

**S-19-002**

**The effect of psilocybin on brain connectivity and emotional processing in healthy volunteers**

Tomas Palenicek, Czech Republic

**S-19-003**

**Psilocybin for the treatment of depression**

Robin Carhart-Harris, United Kingdom

## Preliminary Scientific Programme / Symposia

### S-19-004

**Exploring the therapeutic potential of ayahuasca in the treatment of psychiatric disorders**

*Jordi Riba, Spain*

### T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC/CLINICAL

#### S-20

08:30–10:00

**Affective and psychotic psychopathology from pregnancy to early adulthood: The dynamic developmental interplay between genes, structures and functions**

*Chair: Paolo Brambilla, Italy*

*Co-Chair: Michael Kaess, Germany*

### S-20-001

**Can personality and parental care impact on brain development?**

*Paolo Brambilla, Italy*

### S-20-002

**Neurodevelopmental trajectories and psychopathology in adolescents and adults who were born very preterm**

*Chiara Nosarti, United Kingdom*

### S-20-003

**Grin2b mediates susceptibility to affective problems in children and adolescents**

*Maria Nobile, Italy*

### S-20-004

**Corollary discharge auditory hallucinations and schizophrenia: A structural network analysis**

*Romy Hemze, Germany*

### T11: DEPRESSION: BASIC/CLINICAL

#### S-21

11:15–12:45

**Measurement-based psychiatry: Toward rating scale-based assessments in the real world**

*Chair: Christoph U. Correll, USA*

*Co-Chair: Søren Dinesen Østergaard, Denmark*

### S-21-001

**Measurement-based care psychiatry: Where are we at and where should we head?**

*Andrew A. Nierenberg, USA*

### S-21-002

**Measurement-based care versus standard care for major depression: Conducting a success randomized controlled trial with blind raters**

*Christoph U. Correll, USA*

### S-21-003

**The role for measurement-based care for bipolar disorder in current and future clinical practice**

*Eduard Vieta, Spain*

### S-21-004

**PANSS-6: A new rating scale for both research and clinical care in schizophrenia**

*Søren Dinesen Østergaard, Denmark*

### T43: SCHIZOPHRENIA: BASIC/CLINICAL

#### S-22

11:15–12:45

**Dissecting the shared and non-shared biological features in schizophrenia and autism spectrum disorder**

*Chair: Kenji Tsuchiya, Japan*

*Co-Chair: Manabu Makinodan, Japan*

### S-22-001

**Comparative genetic analysis of autism spectrum disorder and schizophrenia: Focus on rare variants**

*Branko Aleksic, Japan*

### S-22-002

**The genetic overlap between autism and schizophrenia: Focus on common variation**

*Jakob Grove, Denmark*

### S-22-003

**Neurobiological findings in schizophrenia and autism spectrum disorder**

*Ryota Hashimoto, Japan*

### S-22-004

**Neural-immune mechanisms in development and disease**

*Allison Bialas, USA*

### T9: COGNITIVE NEUROSCIENCE

#### S-23

11:15–12:45

**Combining cognitive remediation with brain imaging techniques: Evidence for neural changes or neuroplasticity?**

*Chair: Martin Lepage, Canada*

*Co-Chair: Kamilla Miskowiak, Denmark*

### S-23-001

**Neural markers and predictors of therapeutic change with cognitive enhancement therapy**

*Matcheri Keshavan, USA*

Symposia / Preliminary Scientific Programme

**S-23-002**

**Short-term working memory training for individuals with psychosis: Cognitive and neurophysiological effects**

*Christopher Bowie, Canada*

**S-23-003**

**Randomised trial of low support cognitive training for schizophrenia: Cortical and behavioural outcomes**

*Gary Donohoe, Ireland*

**S-23-004**

**SESAME: A brief intervention for memory in schizophrenia. Behavioral and imaging data**

*Martin Lepage, Canada*

**T4: ANXIETY DISORDERS: BASIC/CLINICAL**

**S-24**

11:15–12:45

**Serotonin and anxiety disorders: Recent evidences from neuroimaging studies**

*Chair: Eduard Maron, Estonia*

*Co-Chair: Tomas Furmark, Sweden*

**S-24-001**

**Serotonin system and panic disorder**

*Eduard Maron, Estonia*

**S-24-002**

**Serotonin system and social anxiety disorder**

*Tomas Furmark, Sweden*

**S-24-003**

**Serotonin system and obsessive-compulsive disorder**

*Oliver Pogarell, Germany*

**S-24-004**

**Serotonin regulation of anxiety neuronal network**

*Andreas Frick, Sweden*

**T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)**

**S-25**

15:00–16:30

**tDCS: From research to clinical practice**

*Chair: Emmanuel Poulet, France*

*Co-Chair: Jerome Brunelin, France*

**S-25-001**

**Translational research on tDCS: Data from a German multisite project**

*Frank Padberg, Germany*

**S-25-002**

**Combining tDCS with neuroimaging**

*Shirley Fecteau, Canada*

**S-25-003**

**Effects of tDCS on biological reactivity to stress and decision making**

*Jerome Brunelin, France*

**S-25-004**

**TDCS in mood disorders – ready to clinical practice? Results from recent phase-III randomised, controlled trials**

*Andre Brunoni, Brazil*

**T33: PHARMACOLOGY**

**S-26**

15:00–16:30

**Into novel drugs for depression**

*Chair: Erich Seifritz, Switzerland*

**S-26-001**

**Conceptual strategies of Big Pharma into innovation in psychiatric therapies: Future leads**

*Siegfried Kasper, Austria*

**S-26-002**

**Personalizing psychiatry treatment**

*Florian Holsboer, Germany*

**S-26-003**

**Psychedelic drugs and clinical markers as innovation road to psychopharmacotherapy**

*Franz X. Vollenweider, Switzerland*

**S-26-004**

**GHB as a candidate drug for stratified depression subtypes**

*Oliver G. Bosch, Switzerland*

**T43: SCHIZOPHRENIA: BASIC/CLINICAL**

**S-27**

15:00–16:30

**Beyond unitary models of psychosis: Confronting complex etiology and dimensionality**

*Chair: Mikhail Pletnikov, USA*

*Co-Chair: John Waddington, Ireland*

**S-27-001**

**Recognising the dimensionality of psychotic illness: Broadening the phenotype to the affective domain**

*Catherine Belzung, France*

**S-27-002**

**Addressing the translational challenge of etiological diversity: Complex gene-environment interactions in risk for psychosis**

*Mikhail Pletnikov, USA*

## Preliminary Scientific Programme / Symposia

### S-27-003

**Closing the translational gap between heritability and genetics: Complex gene-gene interactions in risk for psychosis**

*John Waddington, Ireland*

### S-27-004

**Extending the strategy for translation: Human induced pluripotent stem cells**

*Kristen Brennand, USA*

## T11: DEPRESSION: BASIC/CLINICAL

### S-28

15:00–16:30

**Wake and sleep electroencephalogram provide biomarkers of depression**

*Chair: Axel Steiger, Germany*

*Co-Chair: Thorsten Mikoteit, Switzerland*

### S-28-001

**Central and autonomous nervous system activity in the prediction of antidepressant treatment**

*Sebastian Olbrich, Switzerland*

### S-28-002

**The value of prefrontal theta cordance of resting EEG in the prediction of antidepressant response**

*Martin Brunovsky, Czech Republic*

### S-28-003

**Novel REM-sleep derived biomarkers of depression**

*Thorsten Mikoteit, Switzerland*

### S-28-004

**sLORETA derived from REM sleep EEG as biomarkers for treatment response in depression after antidepressant medication**

*Marcel Pawlowski, Germany*

## T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC/CLINICAL

### S-29

17:00–18:30

**Autism spectrum disorders in adults – from the clinical phenotype to the underlying neurobiology – novel techniques such as phenotype-based genetic variants association studies, high field magnet resonance imaging and 3d brain organoids**

*Chair: Tanja Michel, Denmark*

*Co-Chair: Sophia Frangou, USA*

### S-29-001

**On the outcome, time course and clinical presentation of autism in adults: A longitudinal study of clinical trajectories**

*Marlene Briciet Lauritsen, Denmark*

### S-29-002

**Modulation of the autistic phenotypes in the broader fragile X gene family by accumulated common gene variants**

*Hannelore Ehrenreich, Germany*

### S-29-003

**New insights from proteomics and nanotechnology-3 D brain organoids: A promising new tool for an vitro model for ASD**

*Tanja Michel, Denmark*

### S-29-004

**The role of myelination in neurodevelopmental disorders**

*Sophia Frangou, USA*

## ► Tuesday, 20 June 2017

## T43: SCHIZOPHRENIA: BASIC/CLINICAL

### S-30

08:30–10:00

**Recent insights in schizophrenia physiopathology and treatments**

*Chair: Pierre-Michel Llorca, France*

*Co-Chair: Guillaume Fond, France*

### S-30-001

**Bridging the gap between research and clinical practice: The development of a national network of schizophrenia expert centers**

*Guillaume Fond, France*

### S-30-002

**Schizophrenia pathophysiology: Recent insights from neuroimaging on glutamatergic and neuroinflammatory mechanisms**

*Oliver Howes, United Kingdom*



Symposia / Preliminary Scientific Programme

**S-30-003**

**The influence of hormones on schizophrenia**

*Iris Sommer, The Netherlands*

**S-30-004**

**Novel adjunctive therapy approaches for inflammatory disturbances in psychiatric disorders**

*Michael Berk, Australia*

**T43: SCHIZOPHRENIA: BASIC/CLINICAL**

**S-31**

08:30–10:00

**Duration of untreated psychosis: From neuroimaging to clinical trials**

*Chair: John Kane, USA*

*Co-Chair: Erika Jaaskelainen, Finland*

**S-31-001**

**Is DUP a moderator of effectiveness with comprehensive specialty care in first episode schizophrenia?**

*John Kane, USA*

**S-31-002**

**The impact of DUP on short and long term outcomes in schizophrenia**

*Erika Jaaskelainen, Finland*

**S-31-003**

**Is there a relationship between DUP and brain structure?**

*Aristotle Voineskos, Canada*

**S-31-004**

**MRI resting state functional connectivity and DUP**

*Deepak Sarpal, USA*

**T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)**

**S-32**

08:30–10:00

**New perspectives on transcranial magnetic stimulation in psychiatric disorders**

*Chair: Shinsuke Kito, Japan*

*Co-Chair: Motoaki Nakamura, Japan*

**S-32-001**

**Transcranial magnetic stimulation in the treatment of bipolar depression**

*Shinsuke Kito, Japan*

**S-32-002**

**Clinical and neurobiological effects of Quadripulse Stimulation (QPS) and Theta Burst Stimulation (TBS) in Mood Disorders (MD)**

*Motoaki Nakamura, Japan*

**S-32-003**

**Neurophysiological correlates of various transcranial magnetic stimulation paradigms in patients with psychiatric disorders: In search of novel biomarkers**

*Yoshihiro Noda, Japan*

**S-32-004**

**Combination of computerized cognitive remediation and transcranial magnetic stimulation**

*Akihiro Takamiya, Japan*

**T11: DEPRESSION: BASIC/CLINICAL**

**S-33**

08:30–10:00

**Epigenetic biomarkers for the diagnosis of mood disorders**

*Chair: Tetsuro Ohmori, Japan*

*Co-Chair: Lourdes Fañanás, Spain*

**S-33-001**

**DNA methylation profiles of the Brain-derived Neurotrophic Factor (BDNF) gene as a potent diagnostic biomarker in major depression**

*Manabu Fuchikami, Japan*

**S-33-002**

**Antenatal prediction of postpartum depression with blood DNA methylation biomarkers**

*Zachary Kaminsky, USA*

**S-33-003**

**Blood diagnostic biomarkers for major depressive disorder using multiplex DNA methylation profiles**

*Shusuke Numata, Japan*

**S-33-004**

**Differential methylation and variable methylation in depression: A genome-wide analysis of monozygotic twins**

*Aldo Cordova-Palomera, Spain*

**T40: PSYCHOPATHOLOGY**

**S-34**

08:30–10:00

**Sex hormones and their wide-ranging effects on psychopathology**

*Chair: Andrea Gogos, Australia*

*Co-Chair: Mark Geyer, USA*

**S-34-001**

**Estrogen, raloxifene and schizophrenia**

*Cyndi Shannon Weickert, Australia*

## Preliminary Scientific Programme / Symposia

**S-34-002**

**Cortical gene expression changes underlying estrogen's effect in schizophrenia**

*Andrea Gogos, Australia*

**S-34-003**

**17 $\beta$ -estradiol effects on psychosis-like attentional abnormalities in rats**

*Ina Weiner, Israel*

**S-34-004**

**Sex differences in depression: The role of neuroestrogens**

*Christina Dalla, Greece*

### T27: OBSESSIVE-COMPULSIVE DISORDERS: BASIC / CLINICAL

**S-35**

08:30–10:00

**New insights into the neurobiology and treatment aspects of obsessive compulsive disorder comorbid with schizophrenia and bipolar affective disorder**

*Chair: E. Mohandas, India*

*Co-Chair: Narayan R. Mutalik, India*

**S-35-001**

**Neurobiology of obsessive compulsive disorder comorbid with schizophrenia**

*Narayan R. Mutalik, India*

**S-35-002**

**Evidence based management of obsessive compulsive disorder comorbid with schizophrenia**

*Firoz Kazhungil, India*

**S-35-003**

**Neurobiology of obsessive compulsive disorder comorbid with bipolar disorder**

*Rajan Nishanth Jayarajan, Australia*

**S-35-004**

**Recent updates in the management of obsessive compulsive disorder comorbid with Bipolar Disorder (BP)**

*Pawan Sharma, Nepal*

### T9: COGNITIVE NEUROSCIENCE

**S-36 SYMPOSIUM**

11:15–12:45

**The role of the nucleus accumbens in psychiatry**

*Chair: Jens Kuhn, Germany*

*Co-Chair: Leonhard Schilbach, Germany*

**S-36-001**

**The anatomy of the nucleus accumbens**

*Ioannis Mavridis, Greece*

**S-36-002**

**The role of nucleus accumbens in social cognition**

*Leonhard Schilbach, Germany*

**S-36-003**

**The role of nucleus accumbens in impulsivity**

*Valerie Voon, United Kingdom*

**S-36-004**

**Deep brain stimulation of the nucleus accumbens**

*Sina Kohl, Germany*

### T11: DEPRESSION: BASIC / CLINICAL

**S-37**

11:15–12:45

**Neurobiologic imaging studies of mood disorders, neurogenetics and antidepressant action with positron emission tomography**

*Chair: J. John Mann, USA*

*Co-Chair: Gitte Moos Knudsen, Denmark*

**S-37-001**

**Familial transmission of 5-HT<sub>1A</sub> autoreceptor up-regulation: An impaired serotonergic endophenotype in mood disorders**

*J. John Mann, USA*

**S-37-002**

**Molecular neuroimaging and genetics**

*Gitte Moos Knudsen, Denmark*

**S-37-003**

**cAMP Cascade in major depressive disorder: Downregulation in unmedicated patients and normalization with treatment**

*Robert Innis, USA*

**S-37-004**

**Predictiveness of peripheral and clinical markers for PET measurement of inflammation and monoamine oxidase: Implications for biomarker development**

*Jeffrey Meyer, Canada*

### T43: SCHIZOPHRENIA: BASIC / CLINICAL

**S-38**

11:15–12:45

**Treatment resistant schizophrenia: Definitions, psychobiology and clinical treatment**

*Chair: John Kane, USA*

*Co-Chair: Ofer Agid, Canada*

**S-38-001**

**Methodological issues in clinical trial designs for TRS**

*John Kane, USA*

Symposia / Preliminary Scientific Programme

**S-38-002**

**A longitudinal perspective on the evolution of treatment resistance**

*Ofer Agid, Canada*

**S-38-003**

**The biology of treatment resistance**

*Oliver Howes, United Kingdom*

**S-38-004**

**Definitions and epidemiology of treatment resistance**

*Christoph U. Correll, USA*

**T1: ADDICTIVE DISORDERS**

**S-39**

15:00–16:30

**Current research on the use of cannabinoids**

*Chair: Aviv Weinstein, Israel*

*Co-Chair: Amine Benyamina, France*

**S-39-001**

**Cannabis use disorder and its effects on cognitive function**

*Valerie Curran, United Kingdom*

**S-39-002**

**The relationship between cannabis and psychosis**

*Deepak Cyril D'Souza, USA*

**S-39-003**

**The genetics of cannabis use disorder**

*Amine Benyamina, France*

**S-39-004**

**The effects of chronic use of synthetic cannabinoids on executive brain function**

*Aviv Weinstein, Israel*

**T10: DEMENTIA: BASIC / CLINICAL**

**S-40**

15:00–16:30

**Alzheimer's Disease (AD) pathophysiology, prevention and treatment strategies: Where we stand and where we go?**

*Chair: Jerzy Leszek, Poland*

*Co-Chair: Ramon Cacabelos, Spain*

**S-40-001**

**Pharmacogenetics of cerebrovascular phenotypes of risk in dementia**

*Ramon Cacabelos, Spain*

**S-40-002**

**Insulin resistance in neurodegeneration: The role of p53/miRNA/SIRT1 axis**

*Kazimierz Gasiorowski, Poland*

**S-40-003**

**Alzheimer drug discovery: Targeting synaptic glutamate signaling**

*Markku Kurkinen, USA*

**S-40-004**

**Nanotechnology for early detection and treatment of Alzheimer's Disease (AD): Where we stand and where we go?**

*Jerzy Leszek, Poland*

**T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)**

**S-41**

15:00–16:30

**Electroconvulsive therapy for depression – optimising treatment and maintaining recovery**

*Chair: Declan McLoughlin, Ireland*

*Co-Chair: Pascal Sienaert, Belgium*

**S-41-001**

**The KEEP-WELL Trial: Ketamine for depression relapse prevention following ECT (NCT02414932)**

*Declan McLoughlin, Ireland*

**S-41-002**

**Immediate and long-term outcomes for Brief-pulse (BP) vs Ultrabrief-pulse (UBP) high-dose unilateral ECT: The ResPECT trials' experience**

*Pascal Sienaert, Belgium*

*H.-P. Spaans, E. Verwijk, F. Bouckaert*

**S-41-003**

**Pre- and post-ECT cognitive performance as predictors for outcome and relapse in depression (NTR1304)**

*Esmée Verwijk, The Netherlands*

**S-41-004**

**The PRIDE Trial – Prolonging remission in depressed elderly (NCT01028508): Results from the randomised phase**

*Charles Kellner, USA*

**T22: MOLECULAR NEUROBIOLOGY**

**S-42**

17:00–18:30

**Neuroepigenetic approaches to assess disease risk, mechanism and treatment**

*Chair: Alfonso Buil, Denmark*

*Co-Chair: Jonathan Mill, United Kingdom*

**S-42-001**

**CACNA1C hypermethylation associated with Bipolar Disorder (BD)**

*Anna Starnawska, Denmark*

*D. Demontis, A. Pen, A. Hedemand, A. L. Nielsen,*

## Preliminary Scientific Programme / Symposia

*N. H. Staunstrup, J. Grove, T. D. Als, A. Jarram,  
N. L. O'Brien, O. Mors, A. McQuillin, A. D. Børghlum*

### S-42-002

**Epigenomic trajectories across human brain development: Relevance for schizophrenia and other neurodevelopmental disorders**

*Jonathan Mill, United Kingdom*

### S-42-003

**Neonatal epigenetic profiling in Danish twins discordant for psychiatric disorder**

*Shantel Weinsheimer, Denmark*

*C. Hansen, A. Starnawska, T. Sparsø, W. Mazin,  
M. Bertalan, J. Grauholm, M. Bækvad-Hansen, A. Buil,  
D. M. Hougaard, T. M. Werge*

### S-42-004

**Epigenetics in schizophrenia and association with anti-psychotic response to clozapine**

*Marta Bosia, Italy*

### ► Wednesday, 21 June 2017

#### T2: ANTIDEPRESSANTS: BASIC / CLINICAL

##### S-43

08:30–10:00

**Novel approaches in mechanisms of action of antidepressant treatment**

*Chair: Rainer Rupprecht, Germany*

### S-43-001

**Signal transduction in membranes as mechanism of action of antidepressants**

*Mark Rasenick, USA*

### S-43-002

**Cytoskeleton as target for antidepressants**

*Massimiliano Bianchi, Ireland*

### S-43-003

**Biomarkers during antidepressant treatment**

*Thomas Baghai, Germany*

### S-43-004

**Relevance of P-Glycoprotein and blood brain barrier for antidepressant treatment**

*Carmine Pariante, United Kingdom*

#### T17: GENETICS

##### S-44

08:30–10:00

**Cannabinoid Receptor (CBR) gene variations in neuropsychiatric disorders**

*Chair: Hiroki Ishiguro, Japan*

*Co-Chair: Emmanuel Onaivi, USA*

### S-44-001

**Environmental stressors induce psychosis based on genetic variation of CB2Rs**

*Hiroki Ishiguro, Japan*

### S-44-002

**ECB system alteration in an animal model of autism spectrum disorders**

*Eugene Dennis, USA*

### S-44-003

**Species differences in CBR genes**

*Qing-Rong Liu, USA*

### S-44-004

**CBR genetics: From mice to human subjects**

*Emmanuel Onaivi, USA*

#### T1: ADDICTIVE DISORDERS

##### S-45

08:30–10:00

**Behavioral addictions: Diagnosis, co-morbidity and neurobiology**

*Chair: Michel Lejoyeux, France*

*Co-Chair: Aviv Weinstein, Israel*

### S-45-001

**Internet gaming disorder- addiction, co-morbidity and the brain**

*Aviv Weinstein, Israel*

### S-45-002

**Neuroimaging evidence for considering hypersexuality as an addiction**

*Florence Thibaut, France*

### S-45-003

**New data on phenomenology and psychiatric comorbidity of compulsive buying**

*Michel Lejoyeux, France*

### S-45-004

**The genetic background of gambling behavior**

*Zsolt Demetrovics, Hungary*

*E. Kótyuk, A. Vereczkei, R. Urbán, A. Eisinger, A. Magi,  
G. Kökönyei, A. Veres-Székely, Á. Gyollai, K. Blum,  
M. Sasvári-Székely, C. Barta*

Symposia / Preliminary Scientific Programme

**T50: VIOLENCE: BASIC / CLINICAL**

**S-46**

08:30–10:00

**Neurobiology and psychopharmacology of aggressive behaviour: Where are we?**

Chair: *Stefano Comai, Italy*

Co-Chair: *Gabriella Gobbi, Canada*

**S-46-001**

**Neurobiology and biomarkers of aggression**

*Stefano Comai, Italy*

**S-46-002**

**Clinical management of aggression in childhood and adolescence**

*Florian D. Zepf, Australia*

**S-46-003**

**Drug abuse/dependence and aggressive behaviour**

*Gabriella Gobbi, Canada*

**S-46-004**

**Epilepsy, antiepileptic drugs and aggression**

*Martin J. Brodie, United Kingdom*

**T11: DEPRESSION: BASIC / CLINICAL**

**S-47**

08:30–10:00

**Catecholamines, anhedonia and depression**

Chair: *Jose Luis Ayuso, Spain*

Co-Chair: *Victoria Valdez, Ecuador*

**S-47-001**

**Catecholamines, reward circuits and depression**

*Gregor Hasler, Switzerland*

**S-47-002**

**Positive affects and depression**

*Jorge Tellez-Vargas, Colombia*

**S-47-003**

**Anhedonia and suicide behavior**

*Maurizio Pompili, Italy*

**S-47-004**

**Exploring the role of proinflammatory cytokines in anhedonia**

*Ruby Castilla-Puentes, USA*

**T32: PHARMACOGENETICS**

**S-48**

11:15–12:45

**Pharmacogenetics of drug defense and neuroprotection: From the Neandertal to the modern humans**

Chair: *Julia Stingl, Germany*

Co-Chair: *Magnus Ingelman-Sundberg, Sweden*

**S-48-001**

**The evolutionary aspect of trait biomarkers in drug metabolism and neuroprotection**

*Magnus Ingelman-Sundberg, Sweden*

**S-48-002**

**Pharmacogenetic polymorphisms on behavioral and structural brain phenotypes uncovered by neuroimaging data**

*Roberto Viviani, Austria*

**S-48-003**

**Prevention of drug toxicity to the brain: The vulnerable brain and ADRs of nervous system disorders**

*Julia Stingl, Germany*

**S-48-004**

**Pharmacogenetic factors in neuroprotection during neurodevelopment**

*Karim Barakat, Germany*

**T11: DEPRESSION: BASIC / CLINICAL**

**S-49**

11:15–12:46

**Evidence-based guidelines for treatment of major depressive disorder: Contrasting views across the world**

Chair: *Roumen Milev, Canada*

Co-Chair: *Allan Young, United Kingdom*

**S-49-001**

**A subequatorial view: The new RANZCP guidelines**

*Gin Malhi, Australia*

**S-49-002**

**The evolution of the CANMAT guidelines**

*Raymond Lam, Canada*

**S-49-003**

**The view from the UK: BAP guidelines for Mood Disorders (MD)**

*Allan Young, United Kingdom*

**S-49-004**

**Even the best guidelines don't work unless they are implemented**

*Sagar Parikh, USA*

## Preliminary Scientific Programme / Symposia

### T6: BIPOLAR DISORDERS: BASIC/CLINICAL

#### S-50

11:15–12:45

**Real time assessment of psychopathology and behavior in Bipolar Disorder (BP) using e-mental health technologies**

*Chair:* Lars Kessing, Denmark

*Co-Chair:* Michael Bauer, Germany

#### S-50-001

**Mood instability and Bipolar Disorder (BD): Deriving useful biosignatures from multidimensional, time stamped, streamed data**

*John Geddes, United Kingdom*

#### S-50-002

**Smartphone based ambulatory assessment of early warning signs in Bipolar Disorder (BP)**

*Michael Bauer, Germany*

#### S-50-003

**Smartphones as objective electronic behavioral biomarkers of illness activity in Bipolar Disorder (BP)**

*Lars Kessing, Denmark*

#### S-50-004

**Voice recognition as objective electronic behavioral biomarkers of illness activity in Bipolar Disorder (BP)**

*Maria Fauerholt-Jepsen, Denmark*

### T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

#### S-51

15:00–16:30

**Advances in biomarker development for neurostimulation**

*Chair:* Paul Croarkin, USA

*Co-Chair:* Motoaki Nakamura, Japan

#### S-51-001

**Stimulation-induced neuroplasticity of prefrontal cortex in adult autism spectrum disorder**

*Motoaki Nakamura, Japan*

#### S-51-002

**Glutamatergic biomarker development for repetitive transcranial magnetic stimulation**

*Paul Croarkin, USA*

#### S-51-003

**Neurocognitive effects of major depressive disorder and neurostimulation therapies**

*Shawn McClintock, USA*

#### S-51-004

**Predicting remission of suicidal ideation following Magnetic Seizure Therapy (MST) in patients with treatment-resistant depression**

*Zafiris J. Daskalakis, Canada*

### T3: ANTIPSYCHOTICS: BASIC/CLINICAL

#### S-52

15:00–16:30

**The G protein coupled receptors as a target for psychotropic drugs**

*Chair:* Andrzej Pilc, Poland

*Co-Chair:* Jeffrey P. Conn, USA

#### S-52-001

**Positive allosteric modulators of GPCRs as a novel treatment for schizophrenia**

*Jeffrey P. Conn, USA*

#### S-52-002

**The mGlu5 receptor imaging in schizophrenia and depression**

*Gregor Hasler, Switzerland*

#### S-52-003

**The mGlu2/3 receptor as a novel therapeutic target for treatment-resistant depression**

*Shigeyuki Chaki, Japan*

#### S-52-004

**The allosteric modulation of group III mGlu receptors as target for antipsychotic or antidepressant drugs**

*Andrzej Pilc, Poland*

### T49: SUICIDE: BASIC/CLINICAL

#### S-53

15:00–16:30

**Suicidal behavior: Neurobiological and genetic determinants**

*Chair:* Yogesh Dwivedi, USA

#### S-53-001

**Epigenetic modifications in brain of suicide individuals: Focus on global and site-specific changes in 5-hydroxymethylcytosine**

*Gustavo Turecki, Canada*

#### S-53-002

**Genetics of intermediate phenotypes for suicidal behavior: Focus on impulsivity and aggression**

*Dan Rujescu, Germany*

#### S-53-003

**Toxoplasma gondii seropositivity and suicidal behavior**

*Teodor Postalache, USA*

Symposia / Preliminary Scientific Programme

**S-53-004**

**Non-coding RNAs: Novel epigenetic regulators in suicidal behavior**

*Yogesh Dwivedi, USA*

**T51: PSYCHOPHARMACOLOGY**

**S-54**

17:00–18:30

**Lithium as a neuroprotective agent: When and how?**

*Chair: Galila Agam, Israel*

*Co-Chair: Changlian Zhu, People's Republic of China*

**S-54-001**

**In vivo lithium-induced augments mitochondrial function, reduces neuroinflammation and increases autophagy**

*Galila Agam, Israel*

**S-54-002**

**Lithium as a novel approach to treat developing brain injury**

*Changlian Zhu, China, People's Republic of*

**S-54-003**

*Hui Zhang, USA*

**S-54-004**

*Francoise Croute, France*

**T23: MOOD STABILISERS: BASIC/CLINICAL**

**S-55**

17:00–18:30

**Rediscovering Lithium**

*Chair: David Taylor, United Kingdom*

*Co-Chair: Jonathan Meyer, USA*

**S-55-001**

**The evidence for Lithium's antisuicide properties and impact on mortality**

*Jimmi Nielsen, Denmark*

**S-55-002**

**The evidence for Lithium's neuroprotective properties**

*Barrat Luft, United Kingdom*

**S-55-003**

**What is the risk for end stage renal disease with Lithium: A sophisticated review**

*Ursula Werneke, Sweden*

*M. Ott, E. Salander Renberg, B. Stegmayr*

**S-55-004**

**An update on assessing and managing Lithium's renal effects**

*Jonathan Meyer, USA*

**► Thursday, 22 June 2017**

**T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)**

**S-56**

08:30–10:00

**Clinical effects and neural mechanisms of electroconvulsive therapy in major depression and schizophrenia**

*Chair: Robert Christian Wolf, Germany*

*Co-Chair: Philipp Thomann, Germany*

**S-56-001**

**ECT in major depression and schizophrenia: Indications and clinical effects**

*Dusan Hirjak, Germany*

**S-56-002**

**Effects of ECT on brain structure and function: Lessons from major depressive disorder**

*Robert Christian Wolf, Germany*

**S-56-003**

**ECT-related effects on regional brain volume and structural networks in patients with schizophrenia and major depressive disorder**

*Philipp Thomann, Germany*

**S-56-004**

**Modulation of intrinsic network connectivity by ECT in patients with schizophrenia and major depressive disorder**

*Fabio Sambataro, Italy*

**T6: BIPOLAR DISORDERS: BASIC/CLINICAL**

**S-57**

08:30–10:00

**Causes and consequences of inflammation in Bipolar Disorder (BP)**

*Chair: Lars Kessing, Denmark*

*Co-Chair: Flavio Kapczinski, Brazil*

**S-57-001**

**Peripheral inflammation in Bipolar Disorder (BP): Trait and state related alterations**

*Klaus Munkholm, Denmark*

**S-57-002**

**Targeting mitochondrial inflammation in Bipolar Disorder (BP)**

*Ana Andrezza, Canada*

**S-57-003**

**Relationships between inflammation, elevated body mass index, and depressive relapse in Bipolar Disorder (BP)**

*David Bond, USA*

## Preliminary Scientific Programme / Symposia

**S-57-004**

**Genetic and central nervous system aspects of immune dysregulation in Bipolar Disorder (BP)**

*Bartholomeus Haarman, The Netherlands*

**T51: NEURODEGENERATIVE DISORDERS**
**S-58**

08:30–10:00

**Novel therapeutics for neurodegenerative disorders**

*Chair: Ramon Cacabelos García, Spain*

**S-58-001**

**ASS234, as a new multi-target directed propargylamine for Alzheimer's Disease (AD) therapy**

*José Marco-Contelles, Spain*

**S-58-002**

**EB101 immunotherapy against amyloid: A promising strategy for treating Alzheimer's Disease (AD)**

*Ivan Carrera, Spain*

**S-58-003**

**The Intelligent Pharmacogenetic Card (PGx-iCard) for neuropsychiatric disorders**

*Juan C. Carril, Spain*

**S-58-004**

**Neuroprotective effects of Atremorine in Cerebral Ischemia and Parkinson disease-related models**

*Javier Egea, Spain*

**S-58-005**

**Basic and clinical studies with E-PodoFavalin-15999 (Atremorine®) in Parkinson's Disease: Selective dopaminergic neuroprotection and pharmacogenetics**

*Ramon Cacabelos, Spain*

**T22: MOLECULAR NEUROBIOLOGY**
**S-59**

08:30–10:00

**The relevance of Neuregulin1-ErbB4 signaling for neuropsychiatric pathomechanisms: Converging insights from mouse genetics, physiology, and human studies**

*Chair: Peter Falkai, Germany*

*Co-Chair: Moritz Rossner, Germany*

**S-59-001**

**The relevance of Neuregulin1-ErbB4 signaling for neuropsychiatric pathomechanisms: Insights from human studies**

*Cyndi Shannon Weickert, Australia*

**S-59-002**

**Neuregulin1-ErbB4 signaling: Integration at the network level**

*Beatriz Rico, United Kingdom*

**S-59-003**

**The relevance of Neuregulin1-ErbB4: Insights from mouse physiological analyses**

*Andrés Buonanno, USA*

**S-59-004**

**Neuregulin1-ErbB4 signaling: Insights from mouse genetics**

*Markus Schwab, Germany*

**T22: MOLECULAR NEUROBIOLOGY**
**S-60**

08:30–10:00

**Multi-omics and psychiatry: The missing molecular link**

*Chair: Michaela Filiou, Germany*

*Co-Chair: Anthony Zannas, Germany*

**S-60-001**

**Epigenomics of stress-related disorders: Current evidence, limitations, and future directions**

*Anthony Zannas, Germany*

**S-60-002**

**From proteomics to biological mechanisms involved in schizophrenia**

*Daniel Martins de Souza, Brazil*

**S-60-003**

**Multi-omics driven discovery of pharmacological targets for stress-related disorders**

*Michaela Filiou, Germany*

**S-60-004**

**Role of CYP2C19 in major depressive disorder – translational study**

*Marin Jukic, Sweden*

**T49: SUICIDE: BASIC / CLINICAL**
**S-61**

08:30–10:00

**Suicide: Aspects that burn**

*Chair: Konstantinos Fountoulakis, Greece*

*Co-Chair: Dina Popovic, Spain*

**S-61-001**

**Genetic basis of suicidal behaviour**

*Alessandro Serretti, Italy*

**S-61-002**

**Mixed features and suicidality: Is DSM 5 wrong?**

*Dina Popovic, Spain*



Symposia / Preliminary Scientific Programme

**S-61-003**

**How does clinical prediction of suicidality affect our daily clinical practice?**

*Mark Weiser, Israel*

*M. Davidson*

**S-61-004**

**Suicidality and overlapping geographical maps: Spurious correlations or cues for an underlying biological substrate?**

*Konstantinos Fountoulakis, Greece*

**T49: SUICIDE: BASIC / CLINICAL**

**S-62**

11:00–12:30

**Innovative approaches in suicide research**

*Chair: Philippe Courtet, France*

*Co-Chair: Sidney Kennedy, Canada*

**S-62-001**

**Initiative for research network**

*Sidney Kennedy, Canada*

**S-62-002**

**Neurosciences based phenomenology of suicidal behaviour**

*Philippe Courtet, France*

**S-62-003**

**MeMind project: Ambulatory assessment in suicide behaviour. Do different things to expect different results?**

*Enrique Baca Garcia, Spain*

**S-62-004**

**The use of machine learning and big data to predict suicide**

*Michael Berk, Australia*

**T33: PHARMACOLOGY**

**S-63**

11:00–12:30

**Atypical neurotransmitters in psychiatry: Relevance for future therapeutics**

*Chair: Gregers Wegener, Denmark*

*Co-Chair: Sâmia Joca, Brazil*

**S-63-001**

**Nitric oxide signalling in psychiatric disorders: Evidence from Gene x Environment x Development (GxExD) studies**

*Gregers Wegener, Denmark*

**S-63-002**

**ATP and NO interaction in stress models of depression**

*Sâmia Joca, Brazil*

**S-63-003**

**The endocannabinoid and endovanilloid system in stress-coping responses**

*Fabricio Moreira, Brazil*

**S-63-004**

**Neurotrophins and psychiatric disorders**

*Eero Castrén, Finland*

**T43: SCHIZOPHRENIA: BASIC / CLINICAL**

**S-64**

11:00–12:30

**Operationalizing the dysconnection syndrome: Translational approaches reveal brain network dysfunction in schizophrenia**

*Chair: Bernat Kocsis, USA*

*Co-Chair: Vaibhav Diwadkar, USA*

**S-64-001**

**Dysconnection in rodent models of schizophrenia: Directed connectivity analyses of frequency-tagged oscillatory coupling of frontal-hippocampal signals**

*Bernat Kocsis, USA*

**S-64-002**

**Ketamine disrupts the functional state of corticothalamic systems: A mechanistic model of first-episode psychosis**

*Didier Pinault, France*

**S-64-003**

**Structural and functional brain dysconnectivity predating the onset of psychosis**

*Stefan Borgwardt, Switzerland*

**S-64-004**

**The dynamics of the functional “dysconnectome” in schizophrenia: Network modeling of in vivo fMRI signals**

*Vaibhav Diwadkar, USA*

**T24: NEUROPATHOLOGY**

**S-65**

11:00–12:30

**Cell-type specific epigenetic, proteomic and gene expression signatures in schizophrenia: New findings from post-mortem investigations**

*Chair: Peter Falkai, Germany*

*Co-Chair: Andrea Schmitt, Germany*

**S-65-001**

**Alteration of genome-wide gene expression in hippocampal CA4 pyramidal neurons in schizophrenia**

*Andrea Schmitt, Germany*

## Preliminary Scientific Programme / Symposia

### S-65-002

**Is the energy dysfunction observed in schizophrenia brains being originated in oligodendrocytes?**

*Daniel Martins de Souza, Brazil*

### S-65-003

**Integrated analysis of cell-type specific epigenome-wide methylation changes in schizophrenia brains**

*Theo Kraus, Germany*

*A. Schmitt, J. Spanner, P. Falkai, A. Giese*

### S-65-004

**Epigenetic signatures in the brain of schizophrenia patients**

*Andre Fischer, Germany*

### T33: PHARMACOLOGY

#### S-66

11:00–12:30

**NMDA receptor antagonists in psychiatry**

*Chair: Peter Gass, Germany*

*Co-Chair: Gerard Sanacora, USA*

### S-66-001

**Glutamatergic mechanisms in schizophrenia: Focus on genetics**

*Dan Rujescu, Germany*

### S-66-002

**Insight into Ketamine's effect via cross-species translational neuroimaging**

*Oliver Grimm, Switzerland*

### S-66-003

**Molecular and cellular determinants of the pleiotropic effects of NMDA receptor antagonists**

*Dragos Inta, Germany*

### S-66-004

**Antidepressant effects of NMDA receptor targeting drugs**

*Gerard Sanacora, USA*

### T11: DEPRESSION: BASIC / CLINICAL

#### S-67

11:00–12:30

**Spectrum of Mood Disorders (MD): Where is the place for mixed states?**

*Chair: Trisha Suppes, USA*

### S-67-001

**Mood Disorders (MD) and mixed states: Evolution in diagnostic classification**

*Roger McIntyre, Canada*

### S-67-002

**Bipolar mixed states: Review of clinical presentation, treatment and outcomes**

*Mark Frye, USA*

### S-67-003

**Major depressive disorder with mixed features: Epidemiology, clinical characteristics and prognosis**

*Allan Young, United Kingdom*

### S-67-004

**Major depressive disorder with mixed features: Review of current treatment options**

*Trisha Suppes, USA*

### T25: NEUROIMAGING: GENETIC, FUNCTIONAL, STRUCTURAL

#### S-68

15:00–16:30

**Dynamical brain: How brain complexity changes with aging and mental illness?**

*Chair: Chih-Chieh Yang, USA*

### S-68-001

**Dynamical analysis of brain activity: A new research dimension**

*Chih-Chieh Yang, USA*

### S-68-002

**Assessment of neurophysiological changes with electroconvulsive therapy in mental disorders using nonlinear approach**

*Ryoko Okazaki, Japan*

### S-68-003

**Increasing signal variability during development and its relevance to autism spectrum disorders**

*Tetsuya Takahashi, Japan*

### S-68-004

**Neurophysiological basis of creativity in healthy elderly people using nonlinear approach**

*Kanji Ueno, Japan*

Symposia / Preliminary Scientific Programme

**T19: INFLAMMATION PSYCHIATRY**

**S-69**

15:00–16:30

**Increased intestinal permeability and bacterial translocation in neuro-psychiatric disorders**

Chair: *Michael Maes, Australia*

Co-Chair: *Yolanda Sanz, Spain*

**S-69-001**

**Increased intestinal permeability and bacterial translocation in depression and chronic fatigue syndrome**

*Michael Maes, Thailand*

**S-69-002**

**Increased intestinal permeability and bacterial translocation in chronic stress animal models**

*Javier Caso, Spain*

**S-69-003**

**Increased intestinal permeability and bacterial translocation in neurodevelopmental disorders**

*Yolanda Sanz, Spain*

**S-69-004**

**Increased intestinal permeability and bacterial translocation in schizophrenia**

*Emily Severance, USA*

**T26: NEUROPHYSIOLOGY**

**S-70**

15:00–16:30

**Current use of EEG-based techniques in psychiatry**

Chair: *Martijn Arns, The Netherlands*

Co-Chair: *Adam Wichniak, Poland*

**S-70-001**

**Epilepsy spectrum disorders and episodic psychiatric symptoms**

*Nash N. Boutros, USA*

**S-70-002**

**Results of the international multi-center iSPOT-A study in ADHD: EEG predictors of treatment outcome to methylphenidate**

*Martijn Arns, The Netherlands*

**S-70-003**

**Did the No-Go P300 component help to predict relapse in recently detoxified alcoholic patients?**

*Salvatore Campanella, Belgium*

**S-70-004**

**Polysomnographic measures of sleep in psychiatry: Implications for diagnosis and treatment**

*Adam Wichniak, Poland*

**T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC / CLINICAL**

**S-71**

15:00–16:30

**Sex-specific neuroendocrinological findings in conduct disorder**

Chair: *Sabine Herpertz, Germany*

Co-Chair: *Christine Freitag, Germany*

**S-71-001**

**The brain oxytocin system in intermale and female aggression in rodents**

*Trynke DeJong, Germany*

*I. Neumann*

**S-71-002**

**Sex-specific differences in oxytocin effects on the brain's salience circuit**

*Ruth Schmitt, Germany*

**S-71-003**

**Sex-specific differences and the effects of puberty on emotional processing in adolescents with and without conduct disorder**

*Kerstin Konrad, Germany*

**S-71-004**

**The role of basal and reactive steroid hormones and neuropeptides in female conduct disorder**

*Christine Freitag, Germany*

*A. Martinelli, K. Ackermann, A. Bernhard, FemNAT-CD study team*

**T6: BIPOLAR DISORDERS: BASIC / CLINICAL**

**S-72**

15:00–16:30

**Socio-demographic and clinical differences between Bipolar I and II Disorder (BP) and implications for treatment**

Chair: *Carlo Altamura, Italy*

Co-Chair: *Bernardo Dell'Osso, Italy*

**S-72-001**

**Bipolar I vs II Disorder (BP): Characterization of socio-demographic and clinical variables in Italian and American samples**

*Bernardo Dell'Osso, Italy*

**S-72-002**

**Clinical implications of predominant polarity and polarity index in Bipolar Disorders (BP)**

*Eduard Vieta, Spain*

## Preliminary Scientific Programme / Symposia, Workshops

### S-72-003

**Epidemiology and clinical correlates of suicide and suicide attempts in Bipolar Disorders (BP)**

*Maurizio Pompili, Italy*

### S-72-004

**Do we have evidence for differentiating pharmacological treatment of Bipolar I from Bipolar II Disorder (BP)?**

*Terence Ketter, USA*

### T43: SCHIZOPHRENIA: BASIC / CLINICAL

#### S-73

15:00–16:30

**Neuropathologic implication of abnormal cortico-basal ganglia connectivity in schizophrenia hallucination and its models**

*Chair: Hiroyuki Nawa, Japan*

#### S-73-001

**Neuropathologic implication of pallidal hyperactivity in the auditory abnormality of schizophrenia animal models**

*Hiroyuki Nawa, Japan*

#### S-73-002

**The rat ketamine model of schizophrenia shows aberrant oscillatory activity in the cortico-basal ganglia circuit**

*Miguel Valencia, Spain*

#### S-73-003

**Excess striatal dopamine and aberrant information processing model of psychosis in schizophrenia**

*Jong Yoon, USA*

#### S-73-004

**Subcortical modulation in auditory processing and auditory hallucinations**

*Toshikazu Ikuta, USA*

## Workshops

► **Sunday, 18 June 2017**

### T51: NATIONAL INITIATIVES

#### WS-01

08:30–10:00

**Initiatives from the Spanish Society of Biological Psychiatry: From evidence to experience**

*Chair: Miquel Bernardo, Spain*

*Co-Chair: Ana Gonzalez Pinto, Spain*

#### WS-01-001

**Agitation consensus**

*Eduard Vieta, Spain*

#### WS-01-002

**ECT consensus**

*Mikel Urretavizcaya, Spain*

#### WS-01-003

**Clinical guidelines for adult patients with a severe mental disorder and a comorbid substance use**

*Luis San, Spain*

### T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC / CLINICAL

#### WS-02

10:15–11:45

**New investigations on the relationship between working memory and ADHD**

*Chair: Joseph Biederman, USA*

#### WS-02-001

**Clinical correlates of working memory deficits in youth with and without ADHD**

*Ronna Fried, USA*

#### WS-02-002

**Are working memory deficits and ADHD dissociable?: An fMRI study**

*Joseph Biederman, USA*

#### WS-02-003

**Reduced prefrontal efficiency for visuospatial working memory in attention-deficit/hyperactivity disorder**

*Jeffrey Newcorn, USA*

#### WS-02-004

**Working memory deficits in a prenatal nicotine exposure mouse model**

*Pradeep Bhide, USA*

Workshops / Preliminary Scientific Programme

► Monday, 19 June 2017

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

**WS-03**

11:15–12:45

**Current status of electroconvulsive therapy in the treatment of major psychiatric disorders**

Chair: Yong-Sik Kim, Republic of Korea  
Co-Chair: Pascal Sienaert, Belgium

**WS-03-001**

**Current status on efficacy of ECT**

Hans Mørch Jensen, Denmark

**WS-03-002**

**Mechanism of ECT focused on psychosis**

Ung-Gu Kang, Republic of Korea

**WS-03-003**

**ECT for the treatment resistant psychosis**

In-Won Chung, Republic of Korea

**WS-03-004**

**ECT in catatonia**

Pascal Sienaert, Belgium

T11: DEPRESSION: BASIC / CLINICAL

**WS-04**

15:00–16:30

**Rethinking depression in the Century XXI: Where are we now in biological psychiatry?**

Chair: Victoria Valdez, Argentina  
Co-Chair: Adriana Rivetti, Argentina

**WS-04-001**

**Is depression an inflammatory-metabolic disease?**

Andrea Marquez Lopez Mato, Argentina

**WS-04-002**

**Genetics risk variants for major depressive disorder**

Alejo Corrales, Argentina

**WS-04-003**

**Rethinking depression in the Century XXI**

Victoria Valdez, Argentina

**WS-04-004**

**Serotonergic hypothesis of depression: Is still up-to-date?**

Adriana Rivetti, Argentina

► Tuesday, 20 June 2017

T43: SCHIZOPHRENIA: BASIC / CLINICAL

**WS-05**

08:30–10:00

**Gesture as window to psychosis pathobiology: From aberrant body experience to social interaction**

Chair: Sebastian Walther, Switzerland  
Co-Chair: Vijay Mittal, USA

**WS-05-001**

**Schizophrenia in the flesh: Empirical studies of anomalous bodily self experiences**

So-Hee Park, USA

**WS-05-002**

**Impaired gesture performance in schizophrenia: Neurobiology and clinical consequences**

Sebastian Walther, Switzerland

**WS-05-003**

**The neural correlates of natural social-communicative perception processes in patients with schizophrenia: Understanding, recognition and interpretation of verbal and non-verbal information**

Benjamin Straube, Germany

**WS-05-004**

**What can gesture-speech mismatch tell us about pathophysiology underlying psychosis-risk syndromes?**

Vijay Mittal, USA

T49: SUICIDE: BASIC / CLINICAL

**WS-06**

11:15–12:45

**Neurobiology of suicidal behaviour**

Chair: Leo Sher, USA  
Co-Chair: Zoltan Rihmer, Hungary

**WS-06-001**

**Testosterone and suicidal behavior in men and women**

Leo Sher, USA

**WS-06-002**

**Suicide in men: Clinical and biological correlates**

Zoltan Rihmer, Hungary

**WS-06-003**

**Neuroinflammatory biomarkers of suicidal behavior**

Jussi Jokinen, Sweden

**WS-06-004**

**Endophenotypes of suicidal behavior for genetic research**

Xenia Gonda, Hungary

## Preliminary Scientific Programme / Workshops

### T11: DEPRESSION: BASIC/CLINICAL

#### WS-07

15:00–16:30

#### Merging evidence and clinical practice in management of depression: The CANMAT experience

Chair: *Sidney Kennedy, Canada*

Co-Chair: *Roumen Milev, Canada*

#### WS-07-001

#### Guidelines for Pharmacological Management of Depression

*Raymond Lam, Canada*

#### WS-07-002

#### Making Effective Guidelines: Examples of Evidence-based Dissemination and Implementation Strategies

*Sagar Parikh, USA*

#### WS-07-003

#### Guidelines for the treatment of depression in specific populations: making decisions despite gaps in evidence

*Glenda MacQueen, Canada*

#### WS-07-004

#### Guidelines for the use of complementary and alternative medicines (CAM) in major depression

*Arun Ravindran, Canada*

### T51: NEUROPSYCHOPATHOLOGY

#### WS-08

15:00–16:30

#### Functional neuroanatomy of hallucinations

Chair: *Rajesh Nagpal, India*

Co-Chair: *Harishchandra Gambheera, Sri Lanka*

#### WS-08-001

#### Functional neuroanatomy of auditory hallucinations

*E. Mohandas Warriar, India*

#### WS-08-002

#### Neural signature of visual hallucinations

*Venu Gopal Jhanwar, India*

#### WS-08-003

#### Neural mechanisms of somatic, musical and extracampine hallucinations

*Anukant Mital, India*

#### WS-08-004

#### The neural signature overlap between delusions and hallucinations

*Debashis Ray, India*

### ► Wednesday, 21 June 2017

### T43: SCHIZOPHRENIA: BASIC/CLINICAL

#### WS-09

11:15–12:45

#### Schizophrenia research in Chile

Chair: *Hernan Silva, Chile*

Co-Chair: *Veronica Larach, Chile*

#### WS-09-001

#### BDNF as a biomarker of cognitive function in schizophrenia: A study in Chilean population

*Hernan Silva, Chile*

#### WS-09-002

#### Pragmatic and linguistic disorders in schizophrenia since the first episode

*Eduardo Duran, Chile*

#### WS-09-003

#### Atypical antipsychotics and psychosis spectrum: Chilean experience

*Eugenio Olea, Chile*

#### WS-09-004

#### Universal coverage for schizophrenia: The GES programme in Chile

*Veronica Larach, Chile*

### T43: SCHIZOPHRENIA: BASIC/CLINICAL

#### WS-10

15:00–16:30

#### Evidence for brain stimulation methods in schizophrenia

Chair: *Joachim Cordes, Germany*

Co-Chair: *Christian Plewnia, Germany*

#### WS-10-001

#### Effects of transcranial direct current stimulation (tDCS) on executive functions

*Christian Plewnia, Germany*

#### WS-10-002

#### rTMS for the treatment of negative symptoms in residual schizophrenia

*Joachim Cordes, Germany*

#### WS-10-003

#### The treatment of hallucinations in schizophrenia spectrum disorders

*Iris Sommer, The Netherlands*

#### WS-10-004

#### Predictors of response to ECT in treatment-resistant schizophrenia

*Tomasz Pawelczyk, Poland*

The scientific programme of the WFSBP 2017 Congress will cover the following topics. Within each topic the track may be basic, clinical, interface or conceptual:

- |   |   |
|---|---|
| 1. Addictive Disorders  | 26. Neurophysiology                                     |
| 2. Antidepressants: Basic/Clinical                                | 27. Obsessive-Compulsive Disorders: Basic/Clinical      |
| 3. Antipsychotics: Basic/Clinical                                 | 28. Pain: Basic/Clinical                                |
| 4. Anxiety Disorders: Basic/Clinical                              | 29. Panic Disorders: Basic/Clinical                     |
| 5. Anxiolytics: Basic/Clinical                                    | 30. Personality Disorders: Basic/Clinical               |
| 6. Bipolar Disorders: Basic/Clinical                              | 31. Pharmacoeconomics                                   |
| 7. Childhood & Adolescent Disorders: Basic/Clinical               | 32. Pharmacogenetics                                    |
| 8. Chronobiology and Psychiatry                                   | 33. Pharmacology  |
| 9. Cognitive Neuroscience   | 34. Phototherapy  |
| 10. Dementia: Basic/Clinical                                      | 35. Posttraumatic Stress: Basic/Clinical                |
| 11. Depression: Basic/Clinical                                    | 36. Pregnancy, post partum and new born: Basic/Clinical |
| 12. Eating Disorders: Basic/Clinical                              | 37. Premenstrual Syndrome: Basic/Clinical               |
| 13. Emergency Psychiatry  | 38. Psychogeriatrics                                    |
| 14. Epidemiology  | 39. Psychoneuroimmunology                               |
| 15. Ethics in Biological Psychiatry                               | 40. Psychopathology                                     |
| 16. Forensic Psychiatry   | 41. Psychosurgery                                       |
| 17. Genetics  | 42. Psycho-Oncology                                     |
| 18. Hypnotics: Basic/Clinical                                     | 43. Schizophrenia: Basic/Clinical                       |
| 19. Inflammation Psychiatry                                       | 44. Sexual Disorders: Basic/Clinical                    |
| 20. Liaison Psychiatry  | 45. Sleep Disorders: Basic/Clinical                     |
| 21. Mental Retardation or Chromosomal Aberrations: Basic/Clinical | 46. Somatoform Disorders: Basic/Clinical                |
| 22. Molecular Neurobiology  | 47. Stimulation Methods (ECT, TMS, VNS, DBS)            |
| 23. Mood Stabilisers: Basic/Clinical                              | 48. Stress: Basic/Clinical                              |
| 24. Neuropathology  | 49. Suicide: Basic/Clinical                             |
| 25. Neuroimaging: Genetic, Functional, Structural                 | 50. Violence: Basic/Clinical                            |
|   | 51. Miscellaneous                                       |





## Call for Abstracts for Free Communications and Posters

**Deadline for abstract submission: 6 December 2016**

**Notification of acceptance/rejection: Early March 2017**

Authors of Free Communications or Posters are hereby kindly invited to submit an abstract for contributions to the WFSBP 2017 Congress by using the online submission form on the congress website [www.wfsbp-congress.org](http://www.wfsbp-congress.org).

Please note that online submission is mandatory.

Free Communications and Posters submitted individually and accepted by the International Scientific Programme Committee will be grouped by category topics into thematic sessions in order to promote communication among the presenters and participants and to allow for inspiring discussions.

### FREE COMMUNICATIONS

Free Communications will be selected by the International Scientific Programme Committee after abstract submissions have been reviewed. The 90-minute sessions will be grouped by topics and chaired by selected specialists. The time slot for a single presentation in a Free Communication session is 15 minutes including discussion time. **Only 1 Free Communication abstract may be submitted per author.**

### POSTERS

Each accepted poster will be exhibited at the WFSBP 2017 Copenhagen Congress at the Bella Center. The best posters will be grouped into thematic Guided Poster Tours chaired by renowned specialists. The Guided Poster Tours will give authors the opportunity to present their findings and discuss them with the audience.

**A maximum of 4 posters abstracts may be submitted per author.** The congress will deliver **WFSBP Young Investigator Awards** for the five best posters. Please refer to page 43 for further information.

Please note that accepted abstracts will be published only after completed registration and payment of the congress registration fee. The acceptance of submitted abstracts simultaneously results in binding registration of the speaker to attend the conference. **The registration fee must be paid immediately** after receiving the abstract acceptance, at the **latest until 20 March 2017**. Authors who have not settled the registration fee until that date will be omitted from the scientific programme. **Onsite registration for presenting authors is not possible.**

### GUIDELINES FOR THE PREPARATION OF ABSTRACTS

Please submit your abstracts online and in English, the official language of the WFSBP Congress 2017.

- ▶ Please choose a title that clearly indicates the content of the contribution.
- ▶ Please avoid abbreviations in the title. Abbreviations may be used in the text if they are defined when used first.
- ▶ The author's name (full first name, family name) and place of work (institution, city, country) should be given. Degrees, titles, street addresses, and acknowledgments of support should be omitted, however.
- ▶ The abstract submission must be complete.
- ▶ Please choose a topic from the topic list.
- ▶ The text of the abstract should briefly state: **Objectives** (indicate the purpose of the study or the hypothesis that was tested), **Methods** (include the setting for the study, the subjects, the diagnosis or intervention, and the type of statistical analysis. If references are needed, they should be given in the text), **Results** (present as clearly as possible the outcome of the study and statistical significance if appropriate) and **Conclusions** (briefly discuss the data and emphasize the significance of the results). References need to be given in the text.
- ▶ The length of your abstract is limited to a maximum of 300 words.
- ▶ Please ensure that the abstract does not contain spelling, grammar or scientific errors, as it will be reproduced exactly as submitted. Submitted abstracts will not be edited in any way. If the abstract does not fulfill the necessary requirements it cannot be published.
- ▶ A disclosure of the existence of any significant financial interest or other affiliations with a funding organisation or with a commercial supporter of the session and/or provider of commercial services is required.
- ▶ All abstracts will be published online in the scientific programme of the WFSBP Congress from April 2017.
- ▶ **Only 1 Free Communication Abstract/Young Scientist Award Abstract may be submitted per author.**
- ▶ **A maximum of 4 posters may be submitted by each author.**



**Submission Procedure**

Abstracts for Free Communications, Young Scientist Awards and Posters have to be submitted electronically by using the online form on the congress website

[www.wfsbp-congress.org](http://www.wfsbp-congress.org).

Detailed instructions regarding the electronic submission procedure can be found on the website.

For any further assistance, please contact the congress and exhibition office:

**CPO HANSER**  
SERVICE

Phone: +49-30-300 669-0

Email: [wfsbp2017@cpo-hanser.de](mailto:wfsbp2017@cpo-hanser.de)

**We organize your success**

CPO HANSER SERVICE is specialized in the field of Conference, Event, Destination Management and, ssoiation Management and has been organizing events of any size throughout Germany and worldwide for more than 35 years.

**CPO HANSER**  
SERVICE

CONFERENCE – EVENT – DESTINATION – ASSOCIATION MANAGEMENT

**We offer you:**

- the best congress organization
- state-of-the-art online solutions
- electronic abstract handling
- CME accreditation handling
- effective congress technology
- sponsoring and exhibition acquisition and management
- finance management
- professional tax solutions
- creative event programs
- inhouse graphic design

**BERLIN**

Paulsborner Str. 44  
14193 Berlin, Germany  
phone +49-30-300 669 0  
fax +49-30-305 73 91  
email [berlin@cpo-hanser.de](mailto:berlin@cpo-hanser.de)

**HAMBURG**

Zum Ehrenhain 34  
22885 Barsbüttel, Germany  
phone +49-40-670 882 0  
fax +49-40-670 32 83  
email [hamburg@cpo-hanser.de](mailto:hamburg@cpo-hanser.de)

[www.cpo-hanser.de](http://www.cpo-hanser.de)





## Format Descriptions of the Scientific Sessions

### OPENING LECTURE

The Opening Lecture will be held during the Opening Ceremony on 18 June 2017.

### PLENARY LECTURES

Plenary Lectures are 45-minute sessions held by renowned experts. The speakers have been chosen among the most prominent researchers in the respective field.

### DEBATES

Debates are intended to offer a platform for a lively, yet balanced discussion on controversial issues. A moderator (chairperson) and two speakers (one proponent and one opponent) will state their opinions on different subjects.

### WFSBP TASK FORCE SYMPOSIA

A good number of WFSBP Task Forces have submitted Symposia organised by their key members on issues related to their field of special expertise. All of them have been included in the scientific programme and pertain to Treatment Guidelines, Consensus Statements and other hot topics in their respective thematic areas.

### WFSBP TASK FORCE WORKSHOPS

A good number of WFSBP Task Forces have submitted Workshops organised by their key members on issues related to their field of special expertise. All of them have been included in the scientific programme and pertain to Treatment Guidelines, Consensus Statements and other hot topics in their respective thematic areas.

### SYMPOSIA

Symposia are selected, covering basic, clinical, interface, and conceptual topics of Biological Psychiatry. Symposia are 90-minute sessions and will be organised and chaired by the experts whose proposals are accepted by the International Scientific Programme Committee.

### WORKSHOPS

Workshops are 90-minute highly interactive sessions with an educational focus. This format is designed to give specific regions a platform for presentation and networking.

### FREE COMMUNICATIONS

Authors are invited to submit abstracts on their latest research findings. All submitted abstracts will be reviewed and the best will be selected and allocated to Free Communication Sessions.

### GUIDED POSTER TOURS

Abstracts on new research findings and/or major research efforts are expected to be submitted for the poster category. For those abstracts which will be submitted by young investigators for the poster category, the Local Organising Committee will arrange Guided Poster Tours to give the authors the opportunity to present these findings and discuss them with the audience.

### EDUCATIONAL GRANT SESSIONS

#### (Young Scientists Award Sessions)

These sessions are dedicated to young researchers up to 40 years of age which will be pre-selected via an application process. Herewith the WFSBP is promoting education for talented young researchers. Interactional and practical learning is in the focus of these sessions. The educational grant sessions are open to all congress delegates.

### INDUSTRY SPONSORED SYMPOSIA

These 60- to 90-minute sessions are fully integrated into the congress. The sessions are organised and executed by the pharmaceutical industry by unrestricted educational grants.

### CME ACCREDITATION

An application will be made to the EACCME® for CME accreditation of this event.

## WFSBP Awards

The following WFSBP Awards will be delivered and presented during the 13<sup>th</sup> World Congress of Biological Psychiatry 2017 in Copenhagen.

### ► WFSBP Lifetime Achievement Award in Biological Psychiatry

The WFSBP Lifetime Achievement Award in Biological Psychiatry is intended for senior research scientists (MD, PhD or equivalent) whose lifework has significantly influenced today's field of biological psychiatry. This award is open to members and non-members of the WFSBP. It consists of a monetary award of EUR 1,000.

### ► WFSBP Award for Scientific Excellence of the WFSBP Host

The WFSBP Award for Scientific Excellence of the WFSBP Host is dedicated to an outstanding researcher in the field of Biological Psychiatry originating from the host country of the World Congress of Biological Psychiatry. This award consists of a monetary award of EUR 1,000.

### ► WFSBP Research Prize

The WFSBP Research Prize is intended for WFSBP members (MD, PhD or equivalent) whose current scientific work has had an important impact in the field of clinical and/or basic research in the area of biological psychiatry. This prize consists of a monetary award of EUR 1,000.

### ► WFSBP Award for Excellence in Education

The WFSBP Award for Excellence in Education is to acknowledge outstanding and innovative education in biological psychiatry including the implementation of new interactive media. The WFSBP Education prize is open to all WFSBP members who have improved the education in all fields of Psychiatry. This award consists of a monetary award of EUR 1,000.

### ► WFSBP Young Investigator Awards for the five best posters (under 40 year-old)

An application for the Young Investigator Award is not necessary. All posters will be evaluated at the congress. The awards will go to those presentations that not only provide evidence of innovative research, but which are also well presented.

Please note that presenting authors must register and attend the meeting to be eligible for any of these awards.

Applications must be sent by e-mail to the congress and exhibition office:

**CPO****HANSER**<sup>®</sup>  
SERVICE

Phone: +49-30-300 669-0

Email: [wfsbp2017@cpo-hanser.de](mailto:wfsbp2017@cpo-hanser.de)

**by 6 December 2016** and should include a short summary of the work and a brief CV. The letter should outline the main professional activities and provide key peer review publications. Prizes will be announced during the Opening Ceremony. Poster prizes will be delivered during the Closing Ceremony.

## Congress Information

Congress Registration for the 13<sup>th</sup> World Congress of Biological Psychiatry is available via the congress website at [www.wfsbp-congress.org](http://www.wfsbp-congress.org).

Registration and payment received	Early registration by 25 January 2017 EUR	Late registration by 31 May 2017 EUR	On-site registration after 31 May 2017 EUR
WFSBP Members	530	630	730
Non-Members	630	730	830
Participants from Low-Income Countries*	290	390	490
Trainees**	290	390	490

\* According to the Low-Income-Countries defined by the world bank. Please see the list on the WFSBP website [www.wfsbp-congress.org](http://www.wfsbp-congress.org)

\*\* Trainee / Student status must be confirmed by certificate in writing by head of department and is applicable only for participants born after 1 Jan 1982. Please send your certificate by email or fax to: CPO HANSER SERVICE GmbH, Fax: +49-30-305 73 91, Email: [wfsbp2017@cpo-hanser.de](mailto:wfsbp2017@cpo-hanser.de)

### PAYMENT

When registering for the WFSBP 2017 Congress in Copenhagen, please arrange for payment of the registration fee. All payments should be made in EURO. You may choose between two modes of payment: **credit card payment** or **bank transfer**. Especially for payment made from outside Germany where the congress office is based, we strongly recommend credit card payments as charges for bank transfers may apply twice, once in the country of origin and a second time in Germany.

**Please choose one mode of payment:**

**Credit card:** AMEX, Mastercard or VISA

**or bank transfer to the congress bank account:**

Hanser & Co GmbH w/WFSBP 2017 ZB

Deutsche Bank Privat- u. Geschäftskunden AG, Berlin/

Bank Code: 1007 0024

Account Number: 108 96 97 02

BIC: DEUT DE DB BER

IBAN: DE 45 1007 0024 0108 9697 02

### CONFIRMATION

Upon receipt of the registration and the corresponding payment, the congress office will send a confirmation form which also serves as an invoice. Please show this confirmation of registration at the congress counter when picking up your congress materials.

### CANCELLATION OF CONGRESS PARTICIPATION

Notice of cancellation should be sent in writing only to the Congress Office CPO HANSER SERVICE. In case of cancellation by 25 January 2017 the payment will be refunded, minus a handling charge of 25%. No refund will be made after 25 January 2017.

### ON-SITE REGISTRATION AFTER 31 MAY 2017

On-site registration will be possible but we recommend to register well in advance. Participants who wish to register on-site are advised to arrive early. On-site registration does not entitle participants to receive a delegate bag. On-site registration will be handled on a first-come, first-served basis, priority will be given to pre-registered delegates.

## General Information

### CONGRESS VENUE

Bella Center Copenhagen  
Center Boulevard 5  
2300 Copenhagen S, Denmark  
Entrance: Congress Foyer

### CONGRESS REGISTRATION DESK

The congress counter will be located in the Foyer.

Preliminary opening hours	
Saturday, 17 June 2017	16:00–19:00
Sunday, 18 June 2017	07:30–19:00
Monday, 19 June 2017	08:00–18:30
Tuesday, 20 June 2017	08:00–18:30
Wednesday, 21 June 2017	08:00–18:30
Thursday, 22 June 2017	08:00–17:30

### CONGRESS AND EXHIBITION OFFICE

**CPO**  
**HANSER**  
SERVICE

Phone: +49–30–300 669-0  
Email: [wfsbp2017@cpo-hanser.de](mailto:wfsbp2017@cpo-hanser.de)

### POSTER EXHIBITION

Posters will be displayed from Monday, 19 June to Thursday, 22 June 2017 in Hall A 1 next to the technical exhibition. Each congress day there will be one Guided Poster Tour with the best posters only. The posters selected for the Guided Poster Tour will be displayed in a special area of the congress center. During the review of the abstracts which is done by the Local Organising Committee, the reviewers will indicate the candidates for the Guided Poster Tours. All other posters will be displayed for one entire congress day and grouped according to topics.

Information regarding poster format, set-up and dismantling will be sent to the authors along with their notification of acceptance.

### TECHNICAL EXHIBITION

The WFSBP Congress 2017 will be accompanied by a major technical exhibition taking place in Hall A 1 of the Bella Center. Potential exhibitors can request an exhibition/sponsoring brochure from the exhibition office CPO HANSER SERVICE.

Email: [wfsbp2017@cpo-hanser.de](mailto:wfsbp2017@cpo-hanser.de)

#### Preliminary opening hours

Monday, 19 June 2017	09:00–17:00
Tuesday, 20 June 2017	09:00–17:00
Wednesday, 21 June 2017	09:00–17:00

### CONGRESS INFORMATION SYSTEM / CO CONGRESS ONLINE®

The web based Congress Information System CO CONGRESS ONLINE® has been installed at [www.wfsbp-congress.org](http://www.wfsbp-congress.org)

Prior to the congress, CO CONGRESS ONLINE® will provide information on:

- ▶ Preparation of the congress
- ▶ List of topics
- ▶ Call for abstracts
- ▶ Invited speakers and invited conveners of symposia
- ▶ Preliminary scientific programme
- ▶ Accepted abstracts
- ▶ List of exhibitors
- ▶ Information about the main sponsors
- ▶ Copenhagen
- ▶ Hotel accommodation
- ▶ Travel to Copenhagen
- ▶ Special news
- ▶ Private mailbox

In due time, the final programme will be published on CO CONGRESS ONLINE® which enables each participant to create her/his personal congress programme schedule. CO CONGRESS ONLINE® offers an extensive congress service.



## General Information

### FINAL PROGRAMME

The final programme and abstracts will be published on the Internet at [www.wfsbp-congress.org](http://www.wfsbp-congress.org) prior to the congress.

### WFSBP 2017 CONGRESS APP MOBILE

The WFSBP 2017 Congress App is free for congress participants and provides iPhone/iPad and android smartphone users at WFSBP 2017 in Copenhagen with on-the-go access to the congress. The most up-to-date congress schedule is available at the fingertips during the congress.

### CONGRESS LANGUAGE

The official language of the WFSBP Congress 2017 is English. Simultaneous translation will not be provided.

### LETTER OF INVITATION

The congress will be pleased to send a formal letter of invitation to any registered delegate requesting one. It is understood that such an invitation is intended to help potential delegates to raise funds or to obtain a visa. This does not imply a commitment from the congress to provide any financial support. Letters of invitation may be requested from the congress office.

### VISA

The entry formalities for Denmark vary according to the country of origin. The Ministry of Foreign Affairs of Denmark provides a list of countries that require a visa to enter the country. Please visit the website [http:// um.dk/en](http://um.dk/en).

### OFFICIAL ITALIAN AGENCY

#### For Italian delegates only:

Any Italian pharmaceutical company supporting or participating in a congress abroad, is subjected to an authorization by AIFA (Italian Drug Agency), according to an Italian Government Decree (Decreto Legislativo 219/06 – art. 124). The request of authorization must be submitted within 60 days before the starting date of the event. The appointed agency to collect all applications from pharmaceutical companies and file them with the AIFA is:

AIM Group International – AIM Education S.r.l.

Valentina Disabato/Cristina Ghidoli

Via G. Ripamonti, 129 | 20141 Milan, Italy

Phone: +39–02–56601.288/360

Fax: +39–02–70048585

Email: [aifa@aimgroup.eu](mailto:aifa@aimgroup.eu)

[www.aimgroupinternational.com](http://www.aimgroupinternational.com)

### INSURANCE

Please note that the congress fee does not include insurance. All participants should arrange for their own insurance. Health and accident insurance is strongly recommended and will need to be purchased in the country of origin.

### FORCE MAJEURE

For reasons beyond its control (such as war, strikes, lock-outs, riots or any such civil disturbances, any natural disaster, including but not limited to earthquakes, floods, droughts and typhoons and any other cause of circumstance of whatsoever nature beyond control) that have an impact on the arrangements, timetables or planning of the 13<sup>th</sup> World Congress of Biological Psychiatry (WFSBP 2017) and its corresponding activities in Copenhagen, WFSBP has the right to immediately alter or cancel the activities or events or any of the arrangements, timetables, plans or other items relating directly or indirectly thereto. No party involved shall be entitled to any compensation for damages that result from such alteration or cancellation.

### CURRENCY

The Danish currency is the Danish Krone (DKK). The Danish Krone is pegged to the Euro and convertible on world currency markets. The exchange rate fluctuates daily depending on the money market.

[www.oanda.com](http://www.oanda.com)

### CLIMATE

Copenhagen is in the oceanic climate zone. Summer months are moderately warm and quite pleasant. June is the sunniest month of the year with an average of about eight hours of sunshine a day and the temperature varies between 11°C (52 °F) and 19°C (66°F).

### TRAVEL TO COPENHAGEN AND BELLA CENTER

**By plane** Copenhagen is easy accessible from many European airports with direct flight connections. It is the largest airport in Scandinavia. From Copenhagen Airport it takes 10 minutes to reach the Bella Center. A regional train runs from the airport to Ørestad Station, the train station of the Bella Center.

**By train** Copenhagen Central Station is located in the heart of the city, bordering to the rough but also trendy Vesterbro. It is a gateway to all public transportation in and out and around Copenhagen. From Copenhagen Central Station it takes approx. 10 minutes by metro to reach the Bella Center. The name of the metro station is also Bella Center.

## General Information

**By car** Bella Center is located at Center Boulevard 5, 2300 Copenhagen S. Follow the „Airport Motorway“, E20. The exit to Center Boulevard is number 19 and is called „Ørestad“ with „Bella Center“ listed below.

### PUBLIC TRANSPORTATION IN COPENHAGEN

Public transportation in Copenhagen is reliable, punctual, and it goes everywhere in the city. In Copenhagen the trains, metro and busses (including waterbuses) can be accessed with the same ticket. All you need to know is how many zones you will pass on your journey. Note the metro will take you from the airport to central Copenhagen in only 13 minutes.

### TAXIS TO BELLA CENTER

Bella Center is just a 10 – 15 minute taxi drive from Copenhagen Central Station and not more than 10 minutes from Copenhagen Airport by taxi. A taxi from Bella Center to the city centre costs about DKK 200-250. A taxi from Bella Center to Copenhagen Airport costs about DKK 150-200.



© Chefsamba/Fotolia.com

### HOTELS IN COPENHAGEN

CPO HANSER SERVICE GmbH has reserved a large number of hotel rooms in various hotels in different price categories in Copenhagen. The majority of the hotel rooms are located close to Bella Center.

Reservations will be possible via **CO HotelOnline®** on the website [www.wfsbp-congress.org](http://www.wfsbp-congress.org). Bookings by email or telephone cannot be accepted.

### CPO HANSER SERVICE

**CPO HANSER**  
SERVICE

Phone: +49-30-300 669-0  
Email: [wfsbp2017@cpo-hanser.de](mailto:wfsbp2017@cpo-hanser.de)

### CITY OF COPENHAGEN

Copenhagen is not only the capital of Denmark. It is a cultural and economic center of Northern Europe. More than 1,2 million citizens live in the greater Copenhagen region.

The city is located on the Danish Island „Sælland“ (Danish: Sjælland) and next to the „Øresund“ – a Baltic sea seagate and natural borderline to Sweden. Due to this geographic location, Copenhagen – together with the Swedish city Malmö – represents the binational „Øresund Region“. It is a unique metropolis area, where two countries and cities are connected via the 8 km „Øresund Bridge“.

The Copenhagen Palaces Christiansborg and Amalienborg are the seat of the Danish Parliament and the residence of the Danish Queen Margrethe II. Architecture, design and music make Copenhagen an outstanding cultural hotspot in Northern Europe. It is famous for its innovative improvements which can be seen and experienced throughout the city.

Also, Copenhagen has great museums to offer, for example Louisiana and The National Gallery of Denmark. The Royal Danish Opera, located directly at the harbor front, is combining modern Danish architecture with international performances. The main sightseeing spots and touristic attractions are the Tivoli Gardens, Christiansborg, and of course the „Little Mermaid“ – the famous sculpture of Edvard Eriksen at the waterside.

The University of Copenhagen is offering a wide range of academic disciplines. With over 40,000 students and more than 9,000 employees, the University of Copenhagen is one of the largest institutions of research and education in the Nordic countries.

Due to short distances within the city of Copenhagen, its good public transportation system, and especially the well developed cycle paths, Copenhagen is a convenient place for meetings.



## Dates to remember

6 December 2016	Deadline for abstract submission for free communications and posters
25 January 2017	Deadline early bird registration
31 May 2017	Deadline late registration
18 June 2017	Opening Ceremony and Networking Reception